MarketLineIC - Johnson Johnson - Profile - 120323

Johnson & Johnson
Table of Contents
Johnson & Johnson- Financial and Strategic Analysis Review .....................................3
Company Overview....................................................................................................3
Johnson & Johnson- Key Facts ..................................................................................3
Johnson & Johnson- Business Description ................................................................3
Johnson & Johnson- Major Products and Services ....................................................4
Johnson & Johnson- History ......................................................................................5
Johnson & Johnson- SWOT Analysis ......................................................................33
Johnson & Johnson- Strengths .................................................................................33
Strengths-Leadership position in diverse healthcare segments ............................33
Strengths-Focus on R&D enabling innovative product launches ........................34
Strengths-Financial performance enable it to provide higher returns to its
shareholders..........................................................................................................34
Johnson & Johnson- Weaknesses.............................................................................34
Weaknesses-Overdependence on US ...................................................................34
Johnson & Johnson- Opportunities ..........................................................................35
Opportunities-Contracts and agreements .............................................................35
Opportunities-Global skin care market ................................................................35
Opportunities-Positive outlook for global pharmaceuticals market.....................35
Johnson & Johnson- Threats ....................................................................................36
Threats-Competitive pressures .............................................................................36
Threats-Influx of generics ....................................................................................36
Threats-Medical device regulations in different countries...................................36
Johnson & Johnson- Key Competitors.....................................................................37
Johnson & Johnson- Key Employees.......................................................................37
Johnson & Johnson- Company Statement................................................................44
Johnson & Johnson- Locations & Subsidiaries........................................................47
Head office ...........................................................................................................47
Other Locations & Subsidiaries ...............................................................................47
Johnson & Johnson, Other locations ....................................................................47
Johnson & Johnson, Subsidiaries .............................................................................47
Janssen Biotech, Inc. ............................................................................................47
Cilag AG...............................................................................................................47
Acclarent Inc ........................................................................................................48
Biosense Webster Inc ...........................................................................................48
Ethicon US LLC...................................................................................................48
Johnson & Johnson Vision Care Inc ....................................................................48
Mentor Worldwide LLC.......................................................................................48
Synthes Inc ...........................................................................................................48
Vogue International..............................................................................................48
Summarized Statement.............................................................................................49
Johnson & Johnson, Annual Statements ..................................................................49
Income Statements ...............................................................................................49
Balance Sheet .......................................................................................................49
Published: 26 Feb 2023 Page 1

Extracted: 12 Mar 2023
Johnson & Johnson
Cash Flow.............................................................................................................49
Detailed Statement ...................................................................................................49
Johnson & Johnson, Full Annual Statements...........................................................49
Income Statements ...............................................................................................50
Balance Sheet .......................................................................................................51
Cash Flow.............................................................................................................52
Summarized Interim Statement ................................................................................53
Johnson & Johnson, Summarized Interim Statements .............................................53
Balance Sheet .......................................................................................................53
Cash Flow.............................................................................................................53
Detailed Interim Statement.......................................................................................53
Johnson & Johnson, Detailed Interim Statement .....................................................53
Balance Sheet .......................................................................................................54
Cash Flow.............................................................................................................55
Capital Market Ratios...............................................................................................56
Johnson & Johnson, Capital Market Ratios .............................................................56
Interim Ratios ...........................................................................................................56
Johnson & Johnson, Interim Ratios..........................................................................56
Annual Ratios ...........................................................................................................57
Johnson & Johnson, Annual Ratios..........................................................................57

Johnson & Johnson
Johnson & Johnson- Financial and Strategic Analysis

Review
Company Overview
Johnson & Johnson (J&J or 'the company') is a health care company that develops,
manufactures and markets consumer health care products, pharmaceuticals and
medical devices. It offers pharmaceuticals in the therapeutic areas of immunology,
oncology, neuroscience, infectious diseases and vaccines, pulmonary hypertension,
cardiovascular and metabolism. The company markets its products under Simponi,
Remicade, Stelara, Aveeno, Clean & Clear, Johnson's Adult, Dabao, Le Petite
Marseillais, Neutrogena and Ogx brand names. Its medical devices include general
surgery, biosurgical, endomechanical and energy products; electrophysiology
products, vision products and phthalmic products. The company buy raw material
from multiple sources. J&J distributes its pharmaceutical products, medical devices
and consumer products to retailers, wholesalers, health care professionals and
hospitals and through a network of retail outlets and distributors. It has business
presence across the Americas, Europe, Asia-Pacific and Africa. The company is
headquartered in New Brunswick, New Jersey, the US.
Johnson & Johnson- Key Facts
Johnson & Johnson- Key Facts

Corporate Ticker Symbol,
JNJ[NYSE]
Address Exchange
Telephone 1 732 5242455 No. of Employees 141700
Fax 1 732 2140332 Fiscal Year End January
Revenue (in US$
URL www.jnj.com 94943
Million)
Source : GlobalData Research analysis / © GlobalData Research
Johnson & Johnson- Business Description
Johnson & Johnson (J&J or 'the company') is a manufacturer and marketer of

healthcare products. The company offers a range of medical devices, consumer
healthcare and pharmaceutical products. J&J sells its products through retailers,
wholesalers, hospitals and health care professionals. It has business operations in the
Americas, Europe, Asia-Pacific and Africa.
The company operates through three reportable business segments: Pharmaceutical,

Medical Devices and Consumer Health.
The company’s Pharmaceutical segment produces and markets products in six

therapeutic areas, including immunology (rheumatoid arthritis, inflammatory bowel
disease and psoriasis), infectious diseases and vaccines (HIV/ AIDS), neuroscience
(neurodegenerative disorders, mood disorders and schizophrenia), oncology (prostate
cancer and hematologic malignancies), pulmonary hypertension (pulmonary arterial

Johnson & Johnson
hypertension) and cardiovascular and metabolism (thrombosis and diabetes). The

segment’s major products in include Simponi, Remicade, Stelara, Simponi Aria,
Edurant, Tremfya, Prezista, Intelence, Symtuza, Prezcobix/Rezolsta, Invega
Trinza/Trevicta, Concerta, Risperdal Consta, Invega Sustenna/Xeplion and Zytiga. It
also offers Darzalex, Procrit/Eprex, Velcade, Imbruvica, Xareltoe, Opsumit,
Invokana, Invokamet/Vokanamet and Uptravi. The company distributes these
products directly to retailers, wholesalers, hospitals and health care professionals for
prescription use. In FY2020, the Pharmaceutical segment reported revenue of
US$52,080 million, which accounted for 55.5% of the company’s total revenue.
J&J's Medical Devices segment manufactures and markets products used by

physicians, nurses, hospitals, eye care professionals and clinics. These products
include orthopaedic products, general surgery, biosurgical, endomechanical and
energy products; electrophysiology products for the treatment of cardiovascular
disease; sterilization and disinfection products to reduce surgical infection; and vision
products, including disposable contact lenses and ophthalmic products related to
cataract and laser refractive surgery. The segment distributes its products to
wholesalers, hospitals and retailers. In FY2021, the Medical Devices segment
reported revenue of US$27,060 million, which accounted for 28.9% of the company’s
total revenue.
The company's Consumer Health segment develops, manufactures and markets

products for baby care, oral care, beauty, women's health care and wound care. It also
offers over-the-counter (OTC) pharmaceutical products. The company markets baby
care products under Johnson's brand, Oral care products under Listerine brand, beauty
products under Aveeno, Clean & Clear, Dabao, Johnson's Adult, Le Petite
Marseillais, Neutrogena and Ogx brand names. It sells women's health care products
under Stayfree and Carefree sanitary pads and O.B. tampon brands outside of North
America. The company’s major wound Care brands include Band-Aid and Neosporin.
The company's OTC pharmaceutical products include cold, flu, allergy and heartburn
products, which are marketed under Tylenol, Sudafed, Benadryl, Zyrtec, Motrin IB
ibuprofen and Pepcid brand names. J&J sells its consumer products to both retail
outlets and distributors globally. In FY2021, the Consumer segment reported revenue
of US$14,635 million, which accounted for 4.1% of the company’s total revenue.
Geographically, the company classifies its business operations into four regions: US;
Europe; Asia-Pacific, Africa; and Western Hemisphere excluding US. In FY2021, the
US accounted for 50.3% of the company's total revenue, followed by Europe (25.2%),
Asia-Pacific, Africa (18.4%), and Western Hemisphere excluding US (6.1%).
Johnson & Johnson- Major Products and Services
Johnson & Johnson- Major Products and Services

Products: Brands:
Pharmaceutical products: Aveeno

Products used in the treatment of Clean & clear
immunology, infectious diseases, Dabao
neuroscience, oncology, and cardiovascular Johnson's Adult

Johnson & Johnson
and metabolic diseases Le petite Marseillais

Lubriderm
Medical devices: Neutrogena
Orthopaedic products Roc
General surgery, biosurgical, endochemical Tylenol
and energy products Sudafed
Electrophysiology products to treat Benadryl
cardiovascular disease Zyrtec
Sterilization and disinfection products Motrin IB
Disposable contact lenses Pepcid
Vision Stayfree
Carefree
Consumer products: Band-Aid
Baby care products Neosporin
Oral care products Remicade
Skin care products Simponi
Women's health care products Simponi Aria
Wound care products Stelara
Over the counter pharmaceutical products Incivo
(cold, flu, allergy and heartburn products) Olysio/sovriad
Prezista
Edurant
Prezcobix/Rezolsta
Sirturo
Concerta
Invega Sustenna/Xeplion
Invega Trinza
Risperdal Consta
Velcade
Zytiga
Imbruvica
Darzalex
Yondelis
Procrit (outside the US as Eprex)
Xarelto
Invokana
Invokamet/Vokanamet
Johnson & Johnson- History
Johnson & Johnson- History

Year Event Description
2023 Contracts/Agreements In January, J&J along with Walmart teamed
up with CareSource to launch a new program
supporting Black maternal health across the
state of Georgia.
2023 Asset Purchase In January, J&J acquired the assets of

Johnson & Johnson
Statewide Insurance Corp. in Arizona.

2022 Spin-off In September, J&J announced to spin off its
consumer health business and new company
to be called Kenvue.
2022 Others In July, J&J sold its stake held by Revolve
Wealth Partners LLC.
2022 Asset Purchase In June, J&J acquired the assets of the
Wholesale Brokerage & Binding and
Managing General Underwriting units of
Midlands Management Corporation.
2022 Stake Sale In July, J&J sold 3.5% stake to Strategic
Financial Services Inc.
2022 Stake Sale In July, J&J sold its 300 shares to Annapolis
Financial Services LLC.
2022 Contracts/Agreements In November, J&J agreed to acquire Abiomed
Inc for US$16.6 billion.
2022 Regulatory Approval In August, J&J received the approval from
European Commission for the expanded use
of IMBRUVICA in an all-oral, fixed-duration
treatment combination with venetoclax (I+V)
for adults with untreated chronic lymphocytic
leukaemia.
2022 Regulatory Approval In October, J&J secured approval from US
Food and Drug Administration (FDA) for
treating a type of multiple myeloma.
2022 Others In June, J&J announced to terminate its
agreement with Emergent BioSolutions Inc to
make COVID-19 vaccine for the drugmaker.
2022 Corporate Changes/Expansions In June, J&J announced the launch of the new
J&J Satellite Center for Global Health
Discovery (Satellite Center) at Singapore's
Duke-NUS Medical School, jointly
established by Duke University and the
National University of Singapore.
2021 Contracts/Agreements In October, Johnson & Johnson's subsidiary,
Janssen Biotech, and Xencor entered into an
agreement for the development and
commercialization of plamotamab and XmAb
CD28 bispecific antibody combinations to
treat patients with B-cell malignancies.
2021 Contracts/Agreements In October, Janssen in collaboration with the
KU Leuven Rega Institute and the KU Leuven
Centre for Drug Design and Discovery
announced the publication of new preclinical
data in the journal Nature.
2021 Others In February, J&J's subsidiary, Janssen-Cilag
International submitted Emergency Use

Johnson & Johnson
Listing (EUL) to the WHO to investigate

single-dose Janssen COVID-19 vaccine
candidate.
2021 Others In April, Johnson & Johnson and Bharat
Biotech received approval from the
Philippines’ Food and Drug Administration
for the emergency use of their COVID-19
vaccines.
2021 Regulatory Approval In July, J&J's pharmaceutical unit, Janssen
secured New Zealand's health regulator
Medsafe provisional approval for a
coronavirus vaccine.
2021 Contracts/Agreements In July, J&J and its U.S.-based Janssen
Pharmaceutical Companies announced the
finalization of a nationwide settlement
agreement to resolve opioid-related claims and
litigation by states, cities, counties, and other
subdivisions in the United States.
2021 New Product Approvals In June, Johnson & Johnson along with
Sinopharm, Pfizer BioNTech, AstraZeneca
Covishield, AZD 12225-Korea AstraZeneca
secured the the Zambia Medicines Regulatory
Authority approval for their COVID-19
vaccines to be administered to citizens in
Zambia.
2021 Contracts/Agreements In August, the company and Optellum entered
into a partnership to expand its reach, with the
aim of increasing lung cancer survival rates.
2021 Regulatory Approval In September, J$J secured FDA approval for
Invega Hafyera, a twice-yearly injectable
antipsychotic for adults to treat patient with
schizophrenia.
2021 New Product Approvals In July, J&J's subsidiary the Janssen
Pharmaceutical secured approval from U.S.
Food and Drug Administration for UPTRAVI
injection for intravenous to treat patient with
pulmonary arterial hypertension in adult.
2021 Contracts/Agreements In March, Janssen Pharmaceutica entered an
advance purchase agreement with the African
Vaccine Acquisition Trust to deliver the
single-shot Covid-19 vaccine candidate to 55
member states of the African Union.
2021 Contracts/Agreements In July, Johnson & Johnson and Enel Green
Power Espana entered into a 10-year Pan-
European Virtual Power Purchase Agreement
for the supply of 270 GWh/year of renewable
power.

Johnson & Johnson
2021 Regulatory Approval In May, J&J secured Mexico's health

regulator's emergency use authorization
approval for its COVID-19 vaccine for
emergency use.
2020 Contracts/Agreements In March, the company's Janssen
Pharmaceutical Companies collaborated with
the Beth Israel Deaconess Medical Center to
assist the development of a preventive vaccine
candidate for COVID-19.
2020 Contracts/Agreements In September, Johnson & Johnson and Grand
River Aseptic Manufacturing entered into an
agreement to support the manufacture of its
SARS-CoV-2 vaccine candidate.
2020 Contracts/Agreements In August, J&J entered into an agreement with
The U.S. Department of Health and Human
Services and Department of Defense for
manufacturing and delivery of COVID-19
vaccine candidate.
2020 Contracts/Agreements In August, J&J subsidiary, Vigor Sub, Inc
entered into an agreement to acquire Momenta
Pharmaceuticals for US$6.5 billion.
2020 Regulatory Approval In July, the company's Janssen Pharmaceutical
Companies secured the European Commission
approval for its vaccine regimen to prevent
Ebola virus disease.
2020 Regulatory Approval In November, Johnson & Johnson announced
the submission of application to secure
approval from the U.S. Food and Drug
Administration and European Medicines
Agency for the daratumumab subcutaneous
(SC) formulation, DARZALEX FASPRO in
the US and as DARZALEX SC in the
European Union.
2020 Contracts/Agreements In March, the company's subsidiary, Janssen
Research & Development collaborated with
the US Department of Health and Human
Services and Moderna, a biotechnology
company, to accelerate the development of
vaccines against COVID-19.
2020 Contracts/Agreements In September, Johnson & Johnson along with
Eisai, Boehringer Ingelheim International
GmbH, Merck KGaA, Pfizer Inc, Sanofi,
Roche, AstraZeneca, Bayer, Bristol-Myers
Squibb, bioMerieux, Novartis, Gilead
Sciences, Merck & Co, Eli Lilly, and
GlaxoSmithKline entered into a partnership to
prioritize the safety, science and accessibility
of the potential vaccines to help fight against

Johnson & Johnson
corona pandemic.
2020 Contracts/Agreements In February, J&J's unit Janssen entered into a
partnership with the US HHS to discover
effective drugs for the new coronavirus
disease, Covid-19.
2020 Contracts/Agreements In March, the company's Janssen Pharama
secured a US$456 million contract from The
US government for a coronavirus vaccine.
2020 Contracts/Agreements In April, Johnson & Johnson and Emergent
BioSolutions announced to extend their
collaboration to manufacture its lead
investigational COVID-19 vaccine candidate.
2020 Contracts/Agreements In January, the company Lung Cancer
Initiative entered into an agreement with
Pulmatrix to provide license for accessing a
portfolio of narrow spectrum kinase inhibitors
intended for development in lung cancer
interception.
2020 Contracts/Agreements In November, Johnson & Johnson and the US
Department of Health and Human Services
announced to expand their agreement to
support the next phase of COVID-19 vaccine
candidate research and development.
2020 Contracts/Agreements In March, Johnson & Johnson entered into a
partnership with the Biomedical Advanced
Research and Development Authority to fund
US$1 billion in COVID-19 vaccine and
antiviral treatment research and development.
2020 Contracts/Agreements In February, J&J entered into a partnership
with the Biomedical Advanced Research and
Development Authority to seek the treatment
solutions for COVID-19.
2020 Contracts/Agreements In August, J&J entered into an agreement to
acquire Momenta Pharmaceuticals, Inc for
US$6.5 billion.
2020 Contracts/Agreements In September, Johnson & Johnson entered into
an agreement with the Government of Canada
to supply up to 20 million doses of its
COVID-19 vaccine candidate.
2020 Contracts/Agreements In March, the company partnered with U.S.
Department of Health & Human Services to
supply one billion vaccines globally for
emergency pandemic use.
2020 Contracts/Agreements In March, the company and other life sciences
companies along with Bill & Melinda Gates
Foundation partnered to develop vaccines,
diagnostics to treat COVID-19 pandemic.

Johnson & Johnson
2020 Contracts/Agreements In February, the company, along with a group

of consortium, and organisations partnered
with GlaxoSmithKline to expedite the
development of treatments for tuberculosis
2019 Contracts/Agreements In December, the company signed an
agreement to acquire the remaining stake in
medical equipment manufacturer, Verb
Surgical Inc.
2019 Regulatory Approval In March, J&J secured the US FDA approval
for its SPRAVATO CIII nasal spray to treat
adults with treatment-resistant depression.
2019 Contracts/Agreements In January, Johnson & Johnson Innovation,
Evotec, and Takeda partnered with Dementia
Consortium for drug discovery collaboration
for neurodegenerative diseases.
2019 Acquisitions/Mergers/Takeovers In January, J&J acquired the assets of
Strickland General Agency of Louisiana.
2019 Acquisitions/Mergers/Takeovers In February, the company announced the
acquisition of Innovalens, a Netherlands-based
intraocular lens manufacturer.
2019 Contracts/Agreements In January, the company entered into a
partnership with Veracyte for the development
and commercialisation of new tests to detect
lung cancer.
2019 Acquisitions/Mergers/Takeovers In August, the company in partnership with
Sumerian Partners Limited, and Inqo
Investments Limited acquired South Lake
Medical Centre from Flamingo Horticulture
Limited, valued for Sh100 million.
2019 Contracts/Agreements In March, J&J and Monash University entered
in to a partnership to advance novel
technology for saving lives of women in child
birth.
2019 Acquisitions/Mergers/Takeovers In December, the company acquired TARIS
Biomedical LLC, a US-based biotechnology
company.
2019 New Products/Services In May, Johnson & Johnson Medical Devices
Companies to launch Biosense Webster's
CARTONET.
2019 Divestiture In April, the company completed the
divestiture of its Advanced Sterilization
Products business to Fortive Corporation for
US$2.8 billion.
2019 Contracts/Agreements In August, the company subsidiary, Janssen
Pharmaceutical collaborated with Arrowhead
Pharmaceuticals to begin REEF-1 Phase 2b
Combination Study in Patients for the

Johnson & Johnson
treatment of chronic hepatitis B virus

infection.
2019 Contracts/Agreements In April, J&J acquired surgical robotics
manufacturer, Auris Health for US$3.4
billion.
2018 Acquisitions/Mergers/Takeovers In September, the company through its
subsidiary, Johnson & Johnson Medical
agreed to acquire Emerging Implant
Technologies, a 3D-printed titanium interbody
implants manufacturer for spinal fusion
surgery.
2018 Regulatory Approval n July, the company's subsidiary, Janssen
Pharma received an approval from the US
FDA for its SYMTUZA, a darunavir-based
single-tablet regimen, to treat human
immunodeficiency virus type 1 (HIV-1).
2018 Contracts/Agreements In June, the company's subsidiary, Janssen
Pharmaceutical entered into a licensing
agreement with Saladax Biomedical for
antipsychotic drug testing patents.
2018 Corporate Changes/Expansions In October, J&J opened a new vaccines
facility in Leiden, the Netherlands.
2018 Regulatory Approval In January, the company's daratumumab
(Darzalex) received the drug approval from
the National Institute for Health and Care
Excellence (NICE) for its limited use, through
the Cancer Drugs Fund (CDF).
2018 Contracts/Agreements In October, J&J agreed to acquire Ci:z
Holdings to strengthen its presence in Japan.
2018 Contracts/Agreements In March, the company and Google partnered
to develop low cost surgical robots.
2018 Contracts/Agreements In August, J&J, Wellbeing Foundation Africa
and Liverpool School of Tropical Medicine
partnered for Emergency Obstetrics and
Newborn Care (EmONC) training in
healthcare facilities for expanding across the
Kwara State, Nigeria.
2018 Contracts/Agreements In August, J&J and the London School of
Hygiene & Tropical Medicine (LSHTM)
partnered for the development of a new
generation of mental healthcare professionals
especially in sub-Saharan Africa.
2018 Contracts/Agreements In June, the company entered into an
agreement with the City of Santa Cruz to
study the urban regeneration on the site of
Tenerife Refinery.
2018 Corporate Changes/Expansions In May, the company announced the opening

Johnson & Johnson
of new Asia Pacific Headquarters.

2018 Contracts/Agreements In December, the company and Johnson &
Johnson subsidiary, Janssen Pharmaceuticals
collaborated to treat neurodegenerative
diseases.
2018 Acquisitions/Mergers/Takeovers In February, the company announced the
acquisition of a software-enabled surgery
technologies developer, Orthotaxy.
2018 Divestiture In October, the company sold its LifeScan
business to Platinum Equity, valued for
US$2.1 billion.
2018 New Products/Services In April, Johnson & Johnson Institute
launched a new analytics-based digital
learning platform to improve technical skills
and clinical outcomes helping surgeons.
2017 Contracts/Agreements J&J entered into a definitive transaction
agreement with Actelion, one of the leading
biopharmaceutical companies, to acquire all
the outstanding shares of Actelion. The
products of Actelion complements the
company’s Janssen Pharmaceutical portfolio.
Ethicon entered into a definitive agreement to
acquire Torax Medical, a medical device
company that manufactures and markets the
LINX Reflux Management System (a device
for the surgical treatment of GERD). The
acquisition will enable Ethicon to provide
patients a safe and effective alternative to the
anatomy-altering laparoscopic Nissen
fundoplication surgical procedure.
2017 Others Johnson & Johnson Medical Devices
Companies introduced CareAdvantage, a
holistic, insights-driven approach that help the
US health systems navigate value-based care.
2017 New Products/Services Johnson & Johnson Medical Devices
Companies launched orthopedic episode of
care approach, which leverages the
CareAdvantage capabilities to help health
systems and surgeons reduce costs and
support better clinical output.
2017 Acquisitions/Mergers/Takeovers The company acquired Abbott Medical Optics
(AMO), a wholly-owned subsidiary of Abbott
Laboratories. The transaction included
ophthalmic products in three business
segments: cataract surgery, laser refractive
surgery and consumer eye health. The
acquisition of AMO complements J&J’s
Acuvue contact lens business.

Johnson & Johnson
2017 Contracts/Agreements In August, J&J entered into a partnership with

the Institute of Microbial Technology to
accelerate the discovery of innovative new
treatments for tuberculosis.
2017 New Products/Services In August, Ethicon, a part of the company's
Medical Devices Companies, launched the
ProxiSure Suturing Device, an advanced
laparoscopic suturing device, in U.S.
2017 Acquisitions/Mergers/Takeovers In June, the company announced the
acquisition of Actelion Ltd for US$30 million.
2017 Acquisitions/Mergers/Takeovers J&J’s Ethicon acquired Megadyne Medical
Products, a medical device company that
develops, manufactures and markets
electrosurgical tools used in operating rooms
worldwide. The acquisition complements and
enhances Ethicon’s energy portfolio with wide
range of innovative electrosurgical tools.
2017 New Products/Services In June, the company launched a laundry
detergents for baby clothes in India.
2017 Contracts/Agreements DePuy Synthes Products, part of J&J, entered
into an asset purchase and development
agreement with Interventional Spine, a
manufacturer of expandable cage and
minimally invasive surgery (MIS)
technologies for spinal fusion. Through the
acquisition of Interventional Spine’s
technology, DePuy Synthes Products can
enhance its portfolio of open and minimally
invasive spine surgery solutions.
2017 Contracts/Agreements Janssen Biotech, in partnership with BMS,
announced plans to evaluate daratumumab
(DARZALEX), first CD38-directed cytolytic
antibody, in combination with nivolumab
(opdivo), a checkpoint inhibitor.
2017 Acquisitions/Mergers/Takeovers In October, Integra LifeSciences Holdings
announced the acquisition of Codman
Neurosurgery business from Johnson &
Johnson for US$1.045 billion.
2017 Regulatory Approval In November, the company's prostate cancer
drug abiraterone in combination with standard
hormone therapy received the approval from
the European Medicines Agency for its use in
a first-line treatment for advanced prostate
cancer.
2017 Others DARZALEX (daratumumab) received
positive CHMP opinion for the treatment of
multiple myeloma in patients who have
received at least one prior therapy.

Johnson & Johnson
2017 Contracts/Agreements In September, the company's Janssen

Vaccines & Prevention B.V. and Biomedical
Advanced Research and Development
Authority (BARDA) partnered to advance its
investigational Ebola vaccine regimen.
2017 New Products/Services In May, the company introduced Johnson &
Johnson Our Story at the Powerhouse and
Johnson & Johnson Our Story of interactive
experiences.
2017 Contracts/Agreements In September, J&J entered into a collaboration
with the US Department of Health and Human
Services for the development of a
comprehensive portfolio of therapeutics and
vaccines to protect from influenza pandemic
and other infectious disease threats.
2017 Contracts/Agreements In November, Johnson & Johnson subsidiary
Ethicon US LLC received a contract for
medical surgical products.
2017 Contracts/Agreements DePuy Synthes Sales announced exclusive co-
promotional agreement with Pacira
Pharmaceuticals to co-promote EXPAREL, a
long-lasting, non-opioid, local analgesic
administered at the orthopaedic surgical site.
2017 Regulatory Approval The ECHELON FLEX Gripping Surface
Technology (GST) System received clearance
from the FDA to offer both 45mm and 60mm
endocutters with exclusive reloads.
2016 Regulatory Approval FDA approved an expansion to Imbruvica’s
(ibrutinib) US prescribing information based
on data supporting its use in patients with
CLL/small lymphocytic lymphoma (SLL). EC
granted conditional approval to Darzalex
(daratumumab) as monotherapy in adult
patients with relapsed and refractory MM,
whose prior therapy included a proteasome
inhibitor (PI) and an immunomodulatory agent
and who have demonstrated disease
progression on the last therapy. CHMP of the
EMA adopted a positive opinion,
recommending the use of subcutaneous
Simponi (golimumab) in combination with
methotrexate (MTX). Simponi (golimumab)
and MTX combination is approved for the
treatment of polyarticular juvenile idiopathic
arthritis (pJIA) in children weighing at least
40 kg and those who have not responded
adequately to previous therapy with MTX.
2016 Regulatory Approval In December, the company's Xian-Janssen

Johnson & Johnson
Pharmaceutical secured approval from China

Food and Drug Administration for its
SIRTURO (bedaquiline) for its use in
combination therapy in adult patients.
2016 Others Janssen-Cilag International submitted a
marketing authorization application (MAA) to
the EMA, seeking approval for a new once-
daily darunavir-based single tablet regimen
(STR). The drug is being developed for the
treatment of HIV-1 in adults and adolescents.
Janssen Vaccines & Prevention submitted its
investigational preventive Ebola prime-boost
vaccine regimen for emergency use
assessment and listing (EUAL) to the World
Health Organization (WHO). EUAL helps UN
member states and procurement agencies
determine the acceptability of a specific
vaccine for use in a public health emergency.
2016 Others Janssen-Cilag International received a positive
opinion from the Committee for Medicinal
Products for Human Use (CHMP) of the
EMA, recommending a conditional marketing
authorization for Darzalex (daratumumab) in
the European Union. Also, the CHMP of the
EMA gave a positive opinion recommending
the marketing authorization of Trevicta
(paliperidone palmitate a 3-monthly injection)
in the European Union for the maintenance
treatment of schizophrenia.
2016 Regulatory Approval Prezista’s (darunavir) US prescribing
information was approved and expanded by
the FDA. The expanded prescribing
information includes data and results from a
study that investigated the use of the drug
during pregnancy and the postpartum period.
2016 Contracts/Agreements Janssen Sciences Ireland collaborated with
ViiV to develop and commercialize a two
drug regimen of two long acting, all-injectable
formulations of rilpivirine (a non-nucleoside
reverse transcriptase inhibitor) and
cabotegravir, which is currently under Phase
III. Rilpivirine and cabotegravir combination
is being developed as an alternate option to
the existing standard oral daily regimen of
three drug therapy for HIV.
2016 Plans/Strategy J&J announced restructuring initiatives in its
medical devices businesses, to efficiently meet
the needs of the customers and patients in the

Johnson & Johnson
evolving healthcare marketplace. As part of

this, the company is striving to strengthen its
go-to-market model, accelerate the speed of
innovation, further prioritize key platforms
and geographies, and streamline operations
while maintaining the quality standards.
2016 Acquisitions/Mergers/Takeovers Ethicon acquired NeuWave Medical, a
privately-held medical device company that
manufactures and markets minimally invasive
soft tissue microwave ablation systems. The
transaction aligns with the company’s strategy
of advancing innovation and investing in areas
of unmet medical needs, including surgical
oncology.
2016 Regulatory Approval Janssen-Cilag International, announced the
EC’s approval of Imbruvica (ibrutinib) for the
treatment of adult patients with previously
untreated CLL. This approval broadened the
indication beyond the initial CLL approval by
the EC in 2014. Further, EC also approved the
use of Trevicta (paliperidone palmitate a 3-
monthly injection) for the maintenance
treatment of schizophrenia in adult patients.
2016 Regulatory Approval The FDA approved Stelara (ustekinumab) for
the treatment of moderately to severely active
Crohn’s disease in adults. The drug is
appropriate for patients who have failed or
were intolerant to treatment with
immunomodulators or corticosteroids but
never failed treatment with a tumor necrosis
factor (TNF) blocker. Stelara (ustekinumab)
can also be used in adults with Crohn’s
disease who have failed or were intolerant to
treatment with one or more TNF blockers.
2016 Others Janssen Biotech submitted a biologics license
application (BLA) to the FDA, seeking
approval of sirukumab for the treatment of
adult patients with moderately to severely
active rheumatoid arthritis. Janssen Research
& Development submitted a supplemental
New Drug Application (sNDA) to the FDA
for the treatment of patients with marginal
zone lymphoma (MZL) who require systemic
therapy.
2016 Regulatory Approval Janssen Research & Development announced
that the FDA granted a BTD for esketamine,
an investigational antidepressant medication,
for the treatment of major depressive disorder

Johnson & Johnson
with imminent risk for suicide.

2016 Contracts/Agreements The company entered into a definitive
agreement to acquire Abbott Medical Optics
(AMO), a wholly-owned subsidiary of Abbott
Laboratories. The transaction will include
ophthalmic products in three business
segments: cataract surgery, laser refractive
surgery and consumer eye health. The
acquisition of AMO complements J&J’s
Acuvue contact lens business and positions it
as a leader in vision care.
2016 Regulatory Approval Health Canada granted approval for Imbruvica
(ibrutinib) as an oral, once-daily, single-agent
targeted therapy for previously untreated
patients with active CLL. Further, the FDA
also granted a BTD to the immunotherapy
Darzalex (daratumumab) in combination with
lenalidomide (an immunomodulatory agent)
and dexamethasone, or bortezomib (a
proteasome inhibitor) and dexamethasone, for
the treatment of patients with MM who have
received at least one prior therapy.
2016 Others Janssen Biotech submitted a BLA to the FDA,
seeking approval of its guselkumab for the
treatment of adults living with moderate to
severe plaque psoriasis. Janssen-Cilag
International submitted a MAA to the EMA,
seeking approval of guselkumab for the
treatment of moderate to severe plaque
psoriasis in adults.
2016 Regulatory Approval The FDA approved Imbruvica (ibrutinib)
capsules for treatment-naive patients with
chronic lymphocytic leukemia (CLL). This
approval broadened the indication beyond the
initial CLL approval in 2014, for the treatment
of patients with CLL who have received a
minimum of one therapy earlier; and for CLL
patients with del 17p, a genetic mutation
associated with poor treatment outcomes.
With the current approval, Imbruvica
addresses all lines of CLL therapy. Imbruvica
is being jointly developed and commercialized
by Janssen Biotech and Pharmacyclics, an
AbbVie company.
2016 Regulatory Approval The FDA granted priority review designation
for the new drug application (NDA) of
mebendazole (500mg chewable tablet
formulation). Chewable mebendazole tablet is

Johnson & Johnson
being developed for the treatment and

prevention of soil-transmitted helminthiasis
(STH)/intestinal worm infestations in adults
and children aged one year or older.
2016 Regulatory Approval Janssen Biotech submitted a sBLA to the
FDA, seeking approval of STELARA
(ustekinumab) for the treatment of adolescents
with moderate to severe plaque psoriasis.
2016 Regulatory Approval FDA granted emergency use authorization
(EUA) for Idylla Ebola Virus Triage Test
(Idylla EBOV Test). The Idylla EBOV Test
detects the presence of the Ebola Zaire virus
in patients with signs and symptoms of Ebola
virus disease. The test was jointly developed
by Janssen Diagnostics, Biocartis and the
Belgium Institute of Tropical Medicine.
2016 Others Janssen Pharmaceutical submitted a NDA to
the Ministry of Health, Labour and Welfare
(MHLW) in Japan, seeking approval of
sirukumab for the treatment of adult patients
with moderately to severely active rheumatoid
arthritis.
2016 Regulatory Approval Janssen Research & Development, announced
that FDA has granted a fourth breakthrough
therapy designation (BTD) for Imbruvica
(ibrutinib): as monotherapy for the treatment
of patients with chronic graft-versus-host-
disease (cGVHD) after failure of one or more
lines of systemic therapy. The FDA also
granted orphan drug designation (ODD) for
Imbruvica (ibrutinib) for the treatment of
cGVHD.
2016 Contracts/Agreements Janssen Research & Development entered into
a clinical trial collaboration agreement with
Genentech, a member of the Roche Group.
The alliance focuses on conducting two
studies to determine the safety and tolerability
of Darzalex (daratumumab) in combination
with atezolizumab to bind with a protein
called programmed cell death-ligand 1 (PD-
L1). The studies assess the efficacy of this
drug combination in the treatment of MM and
solid tumor.
2016 Regulatory Approval The FDA approved an expanded indication for
Ethicon’s Evarrest Fibrin Sealant Patch.
Evarrest leverages biologics to efficiently stop
problematic bleeding during surgery. The
expanded indication allows the use of the

Johnson & Johnson
product as an adjunctive hemostat across a

broad range of challenging patient types and
surgeries.
2016 Regulatory Approval The FDA approved Invokamet XR, a once-
daily, fixed-dose combination therapy of
canagliflozin and metformin hydrochloride
extended-release for first-line use as an
adjunct to diet and exercise. The therapy
improves blood glucose control in adults with
type 2 diabetes in case of appropriate
treatment with the two medications.
2016 Others Janssen-Cilag International’s Imbruvica
(ibrutibnib) received a positive opinion from
the CHMP of the EMA, recommending
broadening the existing marketing
authorization for the drug as a single agent for
the treatment of adult patients with previously
untreated CLL.
2016 Plans/Strategy In December, the company plans to open new
technology center in Providence, Rhode
Island.
2016 Others Janssen Biotech submitted a supplemental
biologics license application (sBLA) for
Darzalex (daratumumab) to the FDA. The
application seeks for the expansion of the
current indication, using Darzalex
(daratumumab) in combination with
lenalidomide (an immunomodulatory agent)
and dexamethasone, or bortezomib (a
proteasome inhibitor) and dexamethasone, for
the treatment of patients with MM who have
received at least one prior therapy. Janssen-
Cilag International submitted a type II
variation application to the EMA for Darzalex
(daratumumab). The application seeks to
broaden the existing marketing authorization
of the drug to include treatment of adult
patients with relapsed MM who have received
at least one prior therapy.
2016 Regulatory Approval The EC approved the use of Stelara
(ustekinumab) for the treatment of adult
patients with moderately to severely active
Crohn’s disease. Stelara (ustekinumab) is
approved for the Crohn’s disease patients who
have not shown an adequate response with,
lost response to, or were intolerant to either
conventional therapy or a TNFa antagonist or
have medical contraindications to such

Johnson & Johnson
therapies. The FDA approved Darzalex

(daratumumab) in combination with two
standard of care regimens (lenalidomide and
dexamethasone, or bortezomib and
dexamethasone) for the treatment of patients
with MM who have received at least one prior
therapy.
2016 Acquisitions/Mergers/Takeovers The company acquired NeoStrata Company, a
leading player in dermocosmetics. The
acquisition included NeoStrata's affiliates and
parent company TriStrata, a privately-held
company.
2016 Contracts/Agreements Janssen Biotech entered into a clinical study
collaboration agreement with Bristol-Myers
Squibb (BMS) to evaluate the combination of
two immuno-oncology compounds in patients
with non-small cell lung cancer (NSCLC).
The phase II clinical trial evaluates the
tolerability and efficacy of the combination of
JNJ-64041757 (Janssen's investigational
immunotherapy) and BMS’'s PD-1 immune
checkpoint inhibitor, Opdivo (nivolumab), in
NSCLC patients.
2016 Contracts/Agreements Janssen Biotech entered into a worldwide
collaboration and license agreement with
Tesaro, for exclusive rights to the
investigational compound niraparib in prostate
cancer. According to the terms of the
agreement, Janssen Biotech will have
worldwide rights (excluding Japan) to develop
and commercialize niraparib for use in
prostate cancer.
2016 Research and Development Janssen Research & Development announced
the discontinuation of the phase III
development program for fulranumab in
osteoarthritis pain. The decision was based on
strategic portfolio prioritization of J&J.
2016 Regulatory Approval FDA and Health Canada approved a license
for sale of the OneTouch Vibe Plus insulin
pump and CGM system for the treatment of
patients age two and older living with
diabetes. It is the first insulin pump integrated
with the Dexcom G5 mobile CGM
technology.
2016 New Products/Services Acclarent, part of Johnson & Johnson Medical
Devices Companies, announced the launch of
Acclarent Aera Eustachian Tube Balloon
Dilation System. Acclarent Aera Eustachian

Johnson & Johnson
Tube Balloon Dilation System is the first

balloon dilation intervention approved by the
FDA for eustachian tube dysfunction (ETD).
2016 Others Janssen-Cilag International’s Stelara
(ustekinumab) received a positive opinion
from CHMP of the EMA, recommending its
marketing authorization in the European
Union. Stelara (ustekinumab) is being
developed as a treatment option for adult
patients with moderately to severely active
Crohn's disease who have not responded
adequately with, lost response to, or were
intolerant to either conventional therapy or a
tumor necrosis factor alpha (TNFa) antagonist
or are not tolerant to such therapies.
2016 Acquisitions/Mergers/Takeovers Johnson & Johnson Consumer acquired
Vogue International, a privately-held company
that engages in marketing, development and
distribution of salon-influenced and nature
inspired hair care and other personal care
products. The acquisition included OGX
collection of shampoos, conditioners,
treatments, styling products, body care and
bath products, the FX line of hair styling
products, and the Proganix and Maui Moisture
hair care products. This acquisition
strengthens the company’s global presence in
advanced hair care products category.
2016 Regulatory Approval Janssen Biotech submitted two sBLAs to the
FDA, seeking approval of its SIMPONI ARIA
(golimumab) for the treatment of adults living
with active psoriatic arthritis and the treatment
of adults living with active ankylosing
spondylitis.
2015 Plans/Strategy J&J and IBM announced plans to partner, to
develop virtual coaching solutions and
applications to transform the patient
experience and to provide improved health
outcomes.
2015 Contracts/Agreements Janssen Biotech announced a license
agreement with Alligator Bioscience. As per
the agreement, Janssen Biotech will attain
rights to develop and commercialize ADC-
1013, an immuno-oncology agent.
2015 Regulatory Approval Janssen Pharmaceuticals received an approval
from FDA for Invega Trinza (paliperidone
palmitate), a three-month injection to treat
Schizophrenia. Invega Trinza (paliperidone

Johnson & Johnson
palmitate) is the first and only four-times-a-

year treatment for Schizophrenia.
2015 Regulatory Approval Janssen Biologics received the EC's approval
for Simponi (golimumab), which is used in the
treatment of non-radiographic axial
spondyloarthritis in adult patients. Janssen-
Cilag International received an approval from
the EC for Stelara (ustekinumab), which is
used to treat moderate-to-severe plaque
psoriasis in adolescent patients from the age of
12 years and older.
2015 Incorporation/Establishment J&J, in partnership with Verily Life Sciences,
formed Verb Surgical, an independent surgical
solutions company. Verb Surgical intends to
develop a broad surgical solutions platform
that will incorporate robotic capabilities and
medical device technology for operating room
professionals.
2015 Acquisitions/Mergers/Takeovers Biosense Webster acquired Coherex Medical,
a privately-held medical device company that
develops Coherex WaveCrest Left Atrial
Appendage Occlusion System. The addition of
Coherex WaveCrest System complements
Biosense Webster's portfolio of therapeutic
solutions for patients suffering from atrial
fibrillation.
2015 Regulatory Approval Janssen Biotech received FDA's approval for
Darzalex (daratumumab), an injection used for
the treatment of patients with MM. Darzalex
(daratumumab) is the first human Anti-CD38
monoclonal antibody to treat MM.
2015 Regulatory Approval Janssen-Cilag International received the EC's
approval for Imbruvica (ibrutinib) capsules
that is used in the treatment of WM in adult
patients.
2015 Others Janssen Therapeutics, division of Janssen
Products, submitted an application to FDA
seeking approval to update the label for once-
daily, all-oral Olysio (simeprevir).
2015 Contracts/Agreements Further, Janssen Pharmaceuticals entered into
a definitive collaboration and license
agreement with Bavarian Nordic, to develop
and commercialize a heterologous prime-
boost vaccine for the treatment of Human
Papillomavirus infections. As per the
agreement, Janssen Pharmaceuticals will
conduct clinical development and, subject to
regulatory approval, will also be responsible

Johnson & Johnson
for registration, distribution and

commercialization of the vaccine worldwide.
2015 Divestiture J&J Consumer divested its Splenda brand to
Heartland Food Products Group. The
company divested its Cordis business, one of
the leaders in the development and
manufacture of interventional vascular
technology, to Cardinal Health.
2015 Divestiture Janssen Pharmaceuticals divested its US
license rights to Nucynta (tapentadol),
Nucynta ER (tapentadol) extended-release
tablets and Nucynta (tapentadol) oral solution
to Depomed.
2015 New Products/Services Janssen Research & Development launched
three new research platforms. These platforms
focus on disease prevention, disease
interception, and the microbiome areas.
2015 Regulatory Approval Janssen Biotech received an approval from
FDA for Imbruvica (ibrutinib) capsules, which
is the first therapy to treat patients with
Waldenstrom's macroglobulinemia (WM), a
rare, indolent type of B-cell lymphoma.
Janssen Therapeutics, a division of Janssen
Products, received an approval from FDA for
Prezcobix (darunavir/cobicistat) tablets to
treat HIV-1 along with other antiretroviral
agents.
2015 Regulatory Approval Janssen Biotech received approval from FDA
for Yondelis (trabectedin). Yondelis
(trabectedin) is used to treat patients with
metastatic liposarcoma or leiomyosarcoma,
two common subtypes of soft tissue sarcoma.
2015 Regulatory Approval Janssen Biotech received FDA's approval to
update Simponi Aria (golimumab) label. As
per the revised label, Simponi Aria
(golimumab), when administered along with
methotrexate, shows an improved signs of
patients' physical and emotional well-being as
measured by the SF-36 assessment.
2015 Contracts/Agreements Ethicon entered into a strategic alliance with
Google, to develop surgical robotics for the
benefit of surgeons, patients and health care
systems.
2015 Acquisitions/Mergers/Takeovers J&J acquired Novira Therapeutics (Novira), a
privately-held biopharmaceutical company
that develops novel therapies for the treatment
of chronic hepatitis B virus infection. The
acquisition included Novira's portfolio of

Johnson & Johnson
novel antivirals, including NVR 3-778. Novira

became part of the infectious diseases and
vaccines therapeutic area of the Janssen
Pharmaceutical Companies of the company.
2015 Acquisitions/Mergers/Takeovers Janssen Pharmaceuticals acquired XO1
Limited, a privately-held virtual
biopharmaceutical company that develops the
anti-thrombin antibody ichorcumab. The
acquisition expanded Janssen
Pharmaceuticals' cardiovascular disease
portfolio.
2014 New Products/Services DePuy Synthes Joint Reconstruction, a
division of DePuy Orthopaedics, introduced
three new products for hip, knee and shoulder
replacement.
2014 Regulatory Approval The FDA granted US marketing approval for
Janssen Biotech's Sylvant (siltuximab) for the
treatment of patients with multicentric
Castleman's disease (MCD) who are HIV
negative and human herpesvirus-8 (HHV-8)
negative.
2014 Divestiture J&J completed the divestiture of its Ortho-
Clinical Diagnostics business, a global
provider of solutions for screening,
diagnosing, monitoring and confirming
diseases, to The Carlyle Group for
approximately $4 billion.
2014 Acquisitions/Mergers/Takeovers J&J acquired Alios BioPharma, a privately-
held clinical stage biopharmaceutical
company focused on developing therapies for
viral diseases, for $1.75 billion in cash.
2014 Acquisitions/Mergers/Takeovers Cilag GmbH International, an affiliate of the
Janssen Pharmaceutical Companies of J&J,
acquired Covagen AG, a privately-held, bio-
pharmaceutical company specializing in the
development of multi-specific protein
therapeutics through the FynomAb technology
platform.
2014 Research and Development Janssen R&D and its development partner,
Bayer HealthCare, expanded the EXPLORER
global cardiovascular research program for
Xarelto (rivaroxaban) to include additional
high-risk patient populations.
2014 Contracts/Agreements AstraZeneca, Pharmacyclics and Janssen
entered into clinical trial collaboration, to
evaluate the efficacy and safety of
AstraZeneca's investigational anti-PD-L1
immune checkpoint inhibitor, MEDI4736, in

Johnson & Johnson
combination with Imbruvica (ibrutinib), an

oral Bruton's tyrosine kinase inhibitor, co-
developed and co-commercialized by
Pharmacyclics and Janssen Biotech.
2014 Contracts/Agreements J&J Innovation forged 12 new alliances with
life science companies and research
institutions around the globe to explore early-
stage innovation in a range of therapeutic
areas and across pharmaceuticals, medical
device and diagnostics and consumer
healthcare. Janssen R&D Ireland formed a
collaboration with ViiV Healthcare (ViiV), a
pharmaceutical company specializing in the
development of therapies for HIV, to develop
and commercialize a new single tablet
regimen containing Janssen's non-nucleoside
reverse transcriptase inhibitor, Edurant
(rilpivirine) and ViiV's integrase inhibitor
Tivicay (dolutegravir) as the sole active
ingredients for the maintenance treatment of
people living with HIV.
2014 Regulatory Approval Janssen-Cilag International received the EC's
approval to use Rezolsta (darunavir/cobicistat)
along with the other antiretroviral medicinal
products for the treatment of HIV-1 infection
in adults aged 18 years or older. Later,
Animas Corporation received FDA's approval
for the Animas Vibe insulin pump and
Continuous Glucose Monitoring (CGM)
system, which is used for the management of
insulin-requiring diabetes in adults ages 18
and older. Animas Vibe allows patients to
view glucose data and administer insulin
directly from the pump.
2014 Contracts/Agreements Janssen Pharmaceuticals entered into an
exclusive license agreement with Vertex
Pharmaceuticals (a US-based pharmaceutical
company), for the worldwide development,
manufacturing and commercialization of VX-
787, a novel medicine in Phase II
development for the treatment of influenza A.
2014 Regulatory Approval Olysio (simeprevir) received the European
marketing authorization for the treatment of
adults with hepatitis C genotype 1 and 4
infections.
2014 Corporate Changes/Expansions J&J opened the Asia Pacific Innovation
Center, located in Shanghai, China, with
satellites in Singapore, Australia and Japan.

Johnson & Johnson
2014 Contracts/Agreements DePuy Synthes entered into a commercial

agreement with Blue Belt Technologies, a
global medical technology company
specializing in enabling technologies for
orthopaedic surgery.
2014 Others Janssen Research & Development submitted
NDAs for Yondelis (trabectedin) to the FDA
for the treatment of patients with advanced
soft tissue sarcoma (STS), including
liposarcoma and leiomyosarcoma subtypes,
who have received prior chemotherapy
including an anthracycline; and for three-
month atypical antipsychotic paliperidone
palmitate. Janssen also submitted an
application seeking approval of Simponi in
European Union for non-radiographic axial
spondyloarthritis.
2014 Contracts/Agreements Janssen R&D Ireland announced partnership
with Gilead Sciences to develop once daily,
darunavir-based, single-tablet regimen to treat
people infected with HIV.
2014 Regulatory Approval The FDA granted marketing approval for
Invokamet (canagliflozin/metformin HCl) for
the treatment of adults with type 2 diabetes.
2014 Others Janssen Pharmaceutical submitted
supplemental NDA (sNDA) for once-monthly
atypical long-acting antipsychotic Invega
Sustenna (paliperidone palmitate) to the FDA
for the treatment of schizoaffective disorder as
either monotherapy or adjunctive therapy.
2014 New Products/Services Cordis launched its Incraft AAA Stent Graft
System, an ultra-low profile device for use
during endovascular aneurysm repair (EVAR)
for patients suffering from infrarenal
abdominal aortic aneurysms (AAA).
2014 Regulatory Approval The FDA approved Janssen's sNDAs for the
once-monthly atypical long-acting
antipsychotic Invega Sustenna (paliperidone
palmitate) to treat schizoaffective disorder as
either monotherapy or adjunctive therapy.
2013 Regulatory Approval Janssen Biotech received US marketing
approval for Simponi (golimumab) to treat
ulcerative colitis.
2013 Acquisitions/Mergers/Takeovers Cordis completed the acquisition of Flexible
Stenting Solutions, a developer of flexible
peripheral arterial, venous and biliary stents.
2013 Regulatory Approval Janssen Pharmaceuticals received FDA
approval for Invokana (canagliflozin) for the

Johnson & Johnson
treatment of adults with type 2 diabetes.

2013 Regulatory Approval The EC granted approval for the use of
Velcade (bortezomib) as induction therapy (a
first therapeutic option) in combination with
dexamethasone or thalidomide and
dexamethasone.
2013 Acquisitions/Mergers/Takeovers J&J acquired Aragon Pharmaceuticals, a
privately-held US-based pharmaceutical
discovery and development company focused
on drugs to treat hormonally-driven cancers.
2013 Stake Sale J&J announced the sale of approximately 82
million American Depositary Shares (ADS) of
Elan held by Janssen Pharmaceutical
(Janssen), an affiliate of J&J to Elan. Janssen
received $11.25 per ADS which resulted in an
after-tax gain of approximately $213 million
recorded by J&J in the second quarter of the
year.
2013 Regulatory Approval Janssen Biotech received FDA approval for
Stelara (ustekinumab) alone or in combination
with methotrexate for the treatment of adult
patients (18 years or older) with active
psoriatic arthritis. Janssen-Cilag International
received the EC approval for Stelara, alone or
in combination with methotrexate, for the
treatment of active psoriatic arthritis in adult
patients when the response to previous non-
biological disease-modifying anti-rheumatic
drug therapy is inadequate. Janssen Biologics
received the EC approval for Simponi
(golimumab) for the treatment of moderately
to severely active ulcerative colitis (UC) in
adult patients who have had an inadequate
response to conventional therapy including
corticosteroids and 6-mercaptopurine (6-MP)
or azathioprine (AZA), or who are intolerant
to or have medical contraindications for such
therapies.
2013 Regulatory Approval The EC granted European marketing
authorization for Invokana (canagliflozin) for
the treatment of adults with type 2 diabetes
mellitus, to improve glycaemic control. The
FDA approved Olysio (simeprevir), an
NS3/4A protease inhibitor, for the treatment
of chronic hepatitis C infection as part of an
antiviral treatment regimen in combination
with pegylated interferon and ribavirin in
genotype 1 infected adults with compensated

Johnson & Johnson
liver disease, including cirrhosis, in the US.

2013 Corporate Changes/Expansions The company opened the Johnson & Johnson
Innovation center in Boston, Massachusetts.
2013 New Products/Services DePuy Synthes Trauma, a division of DePuy
Orthopaedics, launched the new Radial Head
Prosthesis System for primary and revision
joint replacement of the radial head to restore
joint function.
2012 Research and Development The company discontinued the phase III
clinical development of bapineuzumab
intravenous (IV) to treat mild-to-moderate
Alzheimer's disease.
2012 Contracts/Agreements Janssen Biotech entered into a license
agreement with Astellas Pharma (Astellas) for
the worldwide development and
commercialization, except in Japan, of
ASP015K, an oral, small molecule Janus
Kinase (JAK) inhibitor.
2012 Acquisitions/Mergers/Takeovers J&J completed the acquisition of Synthes for a
total purchase price of $19.7 billion in cash
and stock. Johnson & Johnson (China)
Investment acquired Guangzhou Bioseal
Biotech (Bioseal), a privately-held
biopharmaceutical company specializing in
the design, development and
commercialization of a porcine plasma-
derived biologic product for controlling
bleeding during surgery. Janssen-Cilag, the
company's subsidiary acquired Corimmun, a
privately-held drug development company in
Germany.
2012 Regulatory Approval Janssen-Cilag International received the
European Commission's (EC’s) marketing
authorization for Dacogen (decitabine), for the
treatment of newly diagnosed de novo or
secondary acute myeloid leukaemia in adult
patients (age 65 years and above).
2011 Acquisitions/Mergers/Takeovers Ethicon Endo-Surgery, a subsidiary of J&J,
acquired SterilMed, a privately-held company
that engages in reprocessing and
remanufacturing of medical devices in the US.
2011 Regulatory Approval The FDA approved Xarelto (rivaroxaban)
tablets, a novel, once-daily, oral anticoagulant
for the prevention (prophylaxis) of deep vein
thrombosis (DVT) which may lead to a
pulmonary embolism (PE) in people
undergoing knee or hip replacement surgery.
2011 Regulatory Approval The FDA granted approvals for J&J's Edurant

Johnson & Johnson
(rilpivirine) tablets for use in combination

with other antiretroviral agents in the
treatment of HIV type 1 (HIV-1) in adults
who have never taken HIV therapy (treatment
naive); and Cordis' Exoseal Vascular Closure
Device in the US.
2011 Product Recall McNeil initiated voluntary recalls at wholesale
level of Tylenol, and certain lots of Benadryl,
Sudafed PE, and Sinutab products distributed
in the US, the Caribbean, and Brazil. These
products were manufactured at the McNeil
plant in Fort Washington, Maryland. In
addition, J&J recalled certain product lots of
Rolaids Multi-Symptom Berry Tablets
distributed in the US, in order to update the
labeling.
2011 Acquisitions/Mergers/Takeovers J&J completed the acquisition of Crucell for a
total consideration of E1.8 billion ($2.4
billion). Crucell became the center for
vaccines within the company's
pharmaceuticals group upon completion of the
acquisition.
2011 Contracts/Agreements J&J signed a definitive merger agreement to
acquire Synthes, a Swiss-based premier global
manufacturer of orthopedic devices. Under the
terms of the agreement, each share of Synthes
common stock, subject to certain conditions,
was agreed to be exchanged for CHF55.65 in
cash and CHF103.35 in J&J common stock.
2011 Acquisitions/Mergers/Takeovers Cilag International, a wholly-owned
subsidiary of J&J, acquired the OTC brands
including Rinza and Doktor Mom of J B
Chemicals & Pharmaceuticals for the
equivalent of approximately $245 million in
cash.
2011 Acquisitions/Mergers/Takeovers J&J's subsidiary McNEIL-PPC and its affiliate
McNeil MMP (McNEIL) gained the full
ownership of the joint venture (JV) between
J&J and Merck Consumer Pharmaceuticals
Co., in the US from Merck Sharp & Dohme
Corp. In addition, J&J's McNeil Consumer
Healthcare Division (McNeil Canada)
acquired its partnership interest in the
Canadian joint venture from Merck Canada.
2011 Acquisitions/Mergers/Takeovers Elanco, a division of Eli Lilly and Company,
completed the acquisition of Janssen Animal
Health business.
2010 Contracts/Agreements J&J made a recommended offer to acquire all

Johnson & Johnson
the outstanding shares of Crucell, a Holland-

based global biopharmaceutical company
focusing on vaccines, proteins and antibodies
that prevent and/or treat infectious diseases, at
a price of E24.8 ($32.9) per share.
2010 Others The Food and Drug Administration (FDA)
sent a warning letter to McNeil Consumer
Healthcare, a J&J company, regarding
significant violations of the current good
manufacturing practice (cGMP) regulations at
its manufacturing facility in Puerto Rico.
2010 Business / Operations Closure McNeil suspended operations at the Fort
Washington plant in connection with the recall
of infants' and children's liquid OTC products
manufactured at the facility.
2010 Acquisitions/Mergers/Takeovers Ethicon, a subsidiary of J&J, completed the
acquisition of Acclarent, a privately-held
medical technology company focusing on the
development of products that address
conditions affecting the ear, nose and throat
(ENT). Centocor Ortho Biotech acquired
RespiVert, a privately-held drug discovery
company focused on developing small-
molecule, inhaled therapies for the treatment
of pulmonary diseases. J&J acquired Micrus
Endovascular, a global developer and
manufacturer of minimally invasive devices to
address hemorrhagic and ischemic stroke, for
approximately $480 million.
2009 Acquisitions/Mergers/Takeovers J&J acquired Mentor, a supplier of medical
products for the global aesthetic market, for
$1.07 billion. The company also acquired
substantially all of the assets and rights of
Elan related to its Alzheimer's immunotherapy
program, through a newly formed company.
2009 Contracts/Agreements J&J and Crucell formed a strategic
collaboration focusing on the discovery,
development and commercialization of
monoclonal antibodies and vaccines for the
treatment and prevention of influenza and
other infectious and non-infectious diseases.
2009 Contracts/Agreements In August, the company terminated co-
development agreement with Alkermes plc for
a four-week long-acting version of anti-
psychotic drug Risperdal Consta (risperidone).
2009 Acquisitions/Mergers/Takeovers J&J completed the acquisition of Cougar
Biotechnology, a development-stage
biopharmaceutical company focusing on

Johnson & Johnson
oncology, for $894 million.

2009 Others J&J agreed to invest $1 billion in Elan in
exchange for newly issued American
Depositary Receipts of Elan representing
18.4% of Elan's outstanding ordinary shares.
2008 New Products/Services Velcade, J&J's blockbuster drug, entered the
EU and Canadian markets as a treatment for
patients with previously untreated multiple
myeloma (MM).
2008 Regulatory Approval The European Medicines Agency (EMA)
granted marketing authorization for J&J's anti-
HIV medication Intelence (etravirine).
2008 Acquisitions/Mergers/Takeovers Johnson & Johnson Nordic, a J&J company,
acquired Amic, a Sweden-based privately held
developer of in-vitro diagnostic technologies
for use in point-of-care and near-patient
settings. Johnson & Johnson (China)
Investment acquired Beijing Dabao
Cosmetics, a China-based personal care
products company, from Beijing Sanlu
Factory and the Beijing Dabao. Veridex
acquired Immunicon, a developer and
marketer of proprietary cell-based research
and diagnostic products with an initial focus
on cancer.
2008 Acquisitions/Mergers/Takeovers J&J acquired HealthMedia, a privately-held
provider of online health coaching. The
company acquired Omrix Biopharmaceuticals,
a developer of biosurgical and immunotherapy
products, for $438 million.
2008 New Products/Services The company launched AMBI Soft & Even
product for hydrate skin and visibly improve
tone and texture; Clean & Clear soft products,
including moisturizing skincare products; and
Sleek and Savvy long PTA balloon dilatation
catheters. Tibotec Therapeutics launched
Prezista for the treatment of HIV.
2007 New Products/Services The company’s Invega (paliperidone)
extended-release tablets, a new atypical
antipsychotic for the treatment of
schizophrenia was launched. Cordis, a J&J
company launched several new products,
including Precise, Nitinol Stent and
Angioguard, emboli capture guidewire to treat
carotid artery disease.
2007 New Products/Services Doribax (doripenem for injection), for
complicated intra-abdominal and complicated
urinary tract infections, including

Johnson & Johnson
pyelonephritis was launched by the company.

J&J also launched Zyrtec (cetirizine HCl), for
the allergy treatment to be used without a
prescription for adults and children.
2006 New Products/Services J&J launched Prezista (darunavir), an anti-
HIV medication.
2006 Acquisitions/Mergers/Takeovers The company bolstered its consumer business
by adding Rembrandt Brand of oral care
products, Gillette, and other major brands
including Listerine, Sudafed, and Neosporin
from Pfizer for $16.6 billion.
2004 Acquisitions/Mergers/Takeovers The company purchased Merck's 50% equity
stake in their European non-prescription
pharmaceuticals joint venture known as
Johnson & Johnson MSD Europe.
2001 Acquisitions/Mergers/Takeovers J&J continued to grow through inorganic
route by acquiring ALZA, a pharmaceutical
and medical systems company.
1999 Acquisitions/Mergers/Takeovers Centocor, a biopharmaceutical company,
became a wholly-owned subsidiary of J&J.
1996 Acquisitions/Mergers/Takeovers The company purchased Cordis, a US-based
medical devices company.
1994 Acquisitions/Mergers/Takeovers The company continued to make strategic,
business-building acquisitions that included
large ones such as Neutrogena (skin care).
1993 Acquisitions/Mergers/Takeovers J&J's skin care business was expanded with
the acquisition of RoC of France.
1991 Incorporation/Establishment The company established Johnson & Johnson
China.
1990 Corporate Changes/Expansions J&J entered China through the establishment
of Shanghai Johnson & Johnson, a joint
venture producing Band-Aid adhesive
bandages in China.
1989 Acquisitions/Mergers/Takeovers Greiter International, a manufacturer of the
PIZ BUIN line of sunscreen and after-sun
products, was added to the J&J family of
companies.
1989 Acquisitions/Mergers/Takeovers The company's consumer businesses, with the
exception of sanitary protection products,
were consolidated to form J&J Consumer
Products Company.
1986 Acquisitions/Mergers/Takeovers The company later acquired Penaten, a baby
toiletries company, and LifeScan.
1974 Acquisitions/Mergers/Takeovers J&J acquired Dr Carl Hahn Company, a
Germany-based manufacturer of sanitary
protection products for women.
1961 Acquisitions/Mergers/Takeovers J&J diversified into prescription

Johnson & Johnson
pharmaceutical business through the purchase

of Janssen Pharmaceutica, a Belgium-based
company with a focus on pharmacological
research and mental health.
1944 Stock Listings/IPO J&J went public and its shares were listed on
the New York Stock Exchange.
1924 Corporate Changes/Expansions The company entered Great Britain, the UK.
1921 New Products/Services J&J launched Band-Aid adhesive bandages,
the first commercial dressings for small
wounds.
1919 Corporate Changes/Expansions International growth was initiated, with the
establishment of an affiliate in Canada.
1898 New Products/Services The company developed an improved
sterilizing technique for catgut sutures.
1896 New Products/Services It manufactured first mass produced sanitary
protection products for women.
1888 New Products/Services The company introduced the first commercial
first aid kits.
1887 Incorporation/Establishment J&J was incorporated.
1886 Incorporation/Establishment J&J was founded by three brothers, Robert
Wood Johnson, James Wood Johnson and
Edward Mead Johnson, in New Brunswick,
New Jersey.
Johnson & Johnson- SWOT Analysis
Johnson & Johnson (J&J or 'the company') is a provider of diverse healthcare

products. Leadership position in diverse healthcare segments, financial performance,
and focus on R&D are the company's major strengths, whereas overdependence on
US and product recall remains the cause for concern. Positive outlook for global
pharmaceuticals market, contracts and agreements, and global skin care market are
likely to offer growth opportunities to the company. However, influx of generics,
medical device regulations in different countries and competitive pressures could
affect its business operations.
Johnson & Johnson- Strengths
Strengths-Leadership position in diverse healthcare segments
The company is one of the largest and diversified healthcare companies in the world.
It has strong presence in the medical devices, pharmaceutical and consumer products
markets worldwide. J&J conducts its business through operating companies in
worldwide. The company manufactures and markets pharmaceutical products in six
therapeutic areas, including immunology, infectious diseases and vaccines, pulmonary
hypertension, neuroscience, oncology, and cardiovascular and metabolism. It offers
medical devices, which are used by physicians, nurses, hospitals, eye care
professionals and clinics worldwide. The company also develops, manufactures and

Johnson & Johnson
markets products for baby care, oral care, beauty, women's health care and wound
care. Strong market position enhances J&J's brand image and enables to penetrate
new markets as new product launches become easier.
Strengths-Focus on R&D enabling innovative product launches
J&J’s research and development (R&D) activities focus on developing new products
in the areas of immunology, infectious, cardiovascular, metabolism, neuroscience and
cancer therapy. The company operates R&D facilities in the US, Brazil, Belgium,
China, Germany, Switzerland Singapore, the UK, France, Israel, Poland, Sweden,
India, Japan, and the Netherlands with additional R&D support in more than 30 other
countries worldwide. In FY2021, the company spent US$14,714 million on its R&D
activities, which as a percentage of revenue, stood at 15.7%. The company's
continued investments in R&D yielded many new pharmaceutical products in the
past. Hence, the company's commitment to technological innovation as reflected in its
R&D investments and a focus on new product development not only strengthens its
market position but also helps it to maintain a robust product pipeline.
Strengths-Financial performance enable it to provide higher

returns to its shareholders
J&J reported revenue of US$93,775 million in FY2021 as compared to US$82,584

million in FY2020, an annual growth of 13.5%. Such growth in revenue was due to
increase of 17.9% in sales in Medical Devices segment, 14.3% in Pharmaceutical, and
4.1% in Consumer segment. Strong growth in revenue increases the company’s ability
to provide higher returns to its shareholders and increases its ability to allocate
adequate funds for future growth initiatives. In FY2021, the company’s operating
margin was 24.3% as compared to 20% in FY2020. Improving operating performance
indicates the company’s focus on efficient cost management. Similarly, the company
reported net profit margin of 22.3% in FY2021 as compared to 17.8%.
Johnson & Johnson- Weaknesses
Weaknesses-Overdependence on US
Overdependence on US could be the major area of concern for the company. Though
the company has business presence across the Americas, Europe, Asia-Pacific and
Africa, it depends on the US for majority of its revenue. In FY2021, the company
generated 50.3% of its revenue from the US. Overdependence on one single
geographic region makes the company susceptible to changes associated with the
economic and political situation of the country. It also exposes the company to
business risks associated with that particular region and negatively impact the
revenue.

Johnson & Johnson
Johnson & Johnson- Opportunities
Opportunities-Contracts and agreements
The company expands its operations and improves its presence through contracts and
agreements. In October 2022, J&J reached a cooperation agreement with Mersana
Therapeutics to jointly develop three new generation ADC drugs. In February 2022,
J&J announced a settlement agreement with the federally recognized Tribes to resolve
their opioid-related claims against the company. In January 2022, Johnson & Johnson
Medical Devices Companies and Microsoft entered into a collaboration to enable its
digital surgery ecosystem. Through this agreement, Microsoft will offer the company
digital surgical solutions, assist in developing its digital surgery platform, and
facilitate device connectivity for the Internet of Things (IoT).
Opportunities-Global skin care market
The company could benefit from the growing global skin care market. The market
underwent a paradigm shift in the recent past, inclining more towards increased
product differentiation and serving a diverse, more conscious and demanding
customer base. According to in-house research, the global skin care market grew
4.3% in 2021 to reach US$ 134,682.2 million and is forecast to reach US$166,463
million in 2026, which indicates an increase of 23.6%. Category wise, facial care is
the largest segment, accounting for 81.7% of the market, followed by body care
(12.2%), hand care (2.7%), depilatories (1.9%) and make-up remover (1.6%) in 2021.
Asia-Pacific accounted for 56.7% of the global skincare market in 2021, followed by
Europe (21.7%), the US (13.3%), Middle East (2.3%), and rest of the world (6%).
P&G manufactures and markets various skin care products including antiperspirants
and deodorants, personal cleansing. It markets these products under Pantene, Head &
Shoulders, Olay, Rejoice, Old Spice, SK-II and Safeguard brand names.
Opportunities-Positive outlook for global pharmaceuticals market
The global pharmaceuticals market has experienced healthy growth in recent years
and expected to grow in the next few years. As per in-house-research the global
pharmaceuticals market is forecast to reach a value of US$1,469.8 billion by 2023
from US$1,111.8 billion in 2018, growing at a CAGR of 5.7% during 2018-2023. The
US accounted for 35.3% of the global pharmaceuticals market value in 2017,
followed by Asia-Pacific (29.2%), Europe (25.8%), Middle East (1.7%) and rest of
the world (8%). Major factors driving the growth include increased specialty drug
innovation, greater patient access to medicines in developing countries and reduced
impact from patent expiry dates. The company stands to benefit from the growing
pharmaceutical industry, which in turn will help drive the company's financial and
operational growth. J&J offers pharmaceutical products in various therapeutic areas,
including immunology, infectious diseases and vaccines, neuroscience, oncology, and
cardiovascular and metabolic diseases. The company stands to benefit from the
growing pharmaceutical industry, which would help drive the company's financial and
operational growth.

Johnson & Johnson
Johnson & Johnson- Threats
Threats-Competitive pressures
J&J operates in a highly competitive pharmaceutical, medical devices and healthcare

industries. The competitive environment in pharmaceutical and consumer healthcare
industries could affect the company’s business operations. The company faces
competition from biotechnology firms, major drug discovery and development firms,
apart from medical devices manufacturers. J&J competes with Abbott Laboratories,
Beiersdorf AG, Boston Scientific Corporation, Bristol-Myers Squibb Company,
Merck & Co, Inc., Eli Lilly and Company, Novartis AG, Pfizer Inc, The Procter &
Gamble Co, and Unilever in the areas of central nervous system, cardiovascular,
gastrointestinal and metabolic disorders, immunology, oncology, hematological
disorders, infectious diseases, medical devices and consumer products. Major factors
influencing competition include changing incentive programs and new product
launches in the market. Such intense competition could affect the company’s business
operations.
Threats-Influx of generics
The pharmaceutical industry across the world is expected to report patent expiries of
large number of innovative drugs in the next few years. Over the last couple of years,
the looming arrival of the "patent cliff" has been haunting the pharmaceutical
industry. As the demand for medicines grows, governments are exerting increasing
pressure on doctors to prescribe cheaper generic medicines. Pharmaceutical
manufacturers will be under pressure to develop generic medicines. This makes
companies undertake changes in their operations such as deploying the scale and
international sourcing capabilities to secure lower prices and better margins on
generics in a way in which legislation typically does not permit branded products. An
increase in generic medicines will have a direct effect on the prescription medicines.
The influx of generics into the market could affect the company’s revenue.
Threats-Medical device regulations in different countries
J&J medical device and pharmaceutical products are subject to various local
transnational and foreign laws and regulations. In the US, the FDA regulates the
launch of new medical devices and pharmaceutical drugs. It also regulates the
manufacturing and labeling and record keeping procedures for healthcare products.
Receiving marketing approval for new healthcare products and drugs from the US
FDA is expensive and time consuming. In Europe, CE marking indicates that a
product meets the essential requirements of all relevant European Medical Device
Directives and is a legal requirement to market a device in the European Union. In
India, the Department of Health under India’s Ministry of Health and Family Welfare
is responsible for the regulation of medical devices. In China, the State Food and
Drug Administration (SFDA) regulates the introduction of new medical products in
the Chinese market. The company has to comply with regulations governing product
standards, import restrictions, packaging and labeling requirements, tariff regulations
and tax requirements. Non-compliance with the regulations and laws or failure to

Johnson & Johnson
maintain, obtain or renew necessary licenses and permits could affect the company's
operations and financial performance.
NOTE:The above strategic analysis is based on in-house research and reflects the
publishers opinion only
Johnson & Johnson- Key Competitors
Abbott Laboratories
Boston Scientific Corporation
Bristol-Myers Squibb Company
Eli Lilly and Company
Merck & Co., Inc.
Pfizer Inc.
The Procter & Gamble Co
Beiersdorf AG
Novartis AG
Johnson & Johnson- Key Employees
Johnson & Johnson- Key Employees

Name Job Title Board Level Since Age Biography
William N. Chief Executive 2022 72 Mr. Hait has been the Executive
Hait External Board Vice President and Chief External
Innovation, Innovation, Medical Safety and
Medical Global Public Health Officer of the
Safety and company since 2022. Prior to this,
Global he served as the Global Head of
Public Johnson & Johnson Global
Health External Innovation from 2018 to
Officer 2022. Previously, he served as the
Global Therapeutic Area Head for
Oncology from 2009 to 2011, and
then as Global Head of Janssen
Research and Development from
2011 to 2018. Mr. Hait joined the
Company in 2007 as Senior Vice
President of Worldwide Head of
Oncology Research.
Ashley Chairman - Executive 2018 51
McEvoy Medical Board
Devices
James Chief Executive 2021 56 Mr. Swanson has been the
Swanson Information Board Executive Vice President and Chief
Officer Information Officer of the company

Johnson & Johnson
since 2021. Prior to this, he served

as Chief Information Officer and
Head of Digital Transformation,
Crop Science at Bayer Crop
Science. Previously, he served as
Chief Information Officer at
Monsanto. Before that, he served as
Vice President IT - Global Human
Health at Merck. Mr. Swanson also
served as the Vice President IT at
Merck Research Labs.
Jennifer Executive Executive 2018 58
Taubert Vice Board
President
Joaquin Chairman Executive 2023 59 Mr. Duato has been the Chief
Duato Board Executive Officer and Chairman of
the company since January 2023.
Prior to this, he served as the Vice
Chairman of the company’s
executive committee. Mr. Duato
also served as the Executive Vice
President, Worldwide Chairman of
Pharmaceuticals since 2016. Before
that, he served in various executive
positions of increasing
responsibility in all business sectors
and across multiple geographies
and functions Janssen-
Farmaceutica S.A.
Vanessa Director Executive 2021 53
Broadhurst Board
Thibaut Executive Executive 2019 52
Mongon Vice Board
President
Nadja West Director Non 2020 60
Executive
Board
Charles Director Non 2006 72 Mr. Prince has been a Director at
Prince Executive J&J since 2006. He served as the
Board Chief Executive Officer at
Citigroup from 2003 to 2007 and
Chairman from 2006 to 2007.
Previously, from 2002 to 2003, Mr.
Prince was the Chairman and Chief
Executive Officer at Citigroup's
Global Corporate and Investment
Bank; and Chief Operating Officer
from 2001 to 2002. He began his

Johnson & Johnson
career as an Attorney at the US

Steel Corporation in 1975. Mr.
Prince is a Director at Xerox and a
member of the Council on Foreign
Relations and The Council of Chief
Executives.
D. Scott Director Non 2014 70 Mr. D. Scott Davis has been a
Davis Executive Director at J&J since 2010. He is
Board currently a Senior Advisor at Apax
Partners, a private equity firm; and
the Non Executive Chairman at
Rolls-Royce Holdings. Mr. Davis
retired from McKinsey & Company
(management consulting) as a
Senior Partner in 2010. He also
served as the Chairman and
Worldwide Managing Director at
McKinsey & Company from 2003
to 2009. Mr. Davis spent over 30
years at McKinsey & Company and
served as a consultant to various
global organizations across the
public, private and not-for-profit
sectors. He also served as the
Managing Partner of McKinsey &
Company's practice in the UK and
Ireland in the past. Currently, Mr.
Davis is a Director at Teach for All,
Majid Al Futtaim Holding, and BP.
Mark A. Director Non 2019 60
Weinberger Executive
Board
Hubert Joly Director Non 2019 62
Executive
Board
Paula A. Director Non 2023
Johnson Executive
Board
Ronald A. Director Non 2011 72 Mr. Williams has been a Director at
Williams Executive J&J since 2011. He served as the
Board Chairman and Chief Executive
Officer at Aetna from 2006 to 2010
and Chairman from 2010 to 2011.
Currently, he serves on the
President Obama's Management
Advisory Board. He is also an
Advisor at Clayton, Dubilier &
Rice, a private equity firm. Mr.

Johnson & Johnson
Williams serves on the Boards at

MIT Corporation, Peterson Institute
for International Economics and on
the Advisory Board at Peterson
Center on Healthcare. Earlier, he
was the Chairman of the Council
for Affordable Quality Healthcare
from 2007 to 2010 and Vice
Chairman at The Business Council
from 2008 to 2010. Mr. Williams
also serves as a Director at The
Boeing Company, American
Express Company and Envision
Healthcare Holdings.
Mary C. Director Non 2015 67 Ms. Beckerle has been a Director at
Beckerle Executive J&J since 2015. Currently, she
Board serves as the Chief Executive
Officer and a Director at Huntsman
Cancer Institute; and an Associate
Vice President for Cancer Affairs
at the University of Utah. She also
serves on the Medical Advisory
Board at the Howard Hughes
Medical Institute; and the Scientific
Advisory Boards of the National
Center for Biological Sciences at
the Tata Institute of Fundamental
Research in India, the
Mechanobiology Institute in
Singapore and the Dana
Farber/Harvard Cancer Center. Ms.
Beckerle serves on the Board of
Directors at the American
Association for Cancer Research.
She also has also been a Director at
Huntsman Corporation since 2011.
Marillyn A. Director Non 2019 68
Hewson Executive
Board
Darius Director Non 2022 56
Adamczyk Executive
Board
Jennifer A. Director Non 2018 58
Doudna Executive
Board
Mark B. Director Non 2013 58 Mr. Mark B. McClellan has been a
McClellan Executive Director at J&J since 2013. He was
Board a Senior Fellow in Economic

Johnson & Johnson
Studies, and Director of the

Initiative on Value and Innovation
in Health Care at the Brookings
Institution from 2007 until 2015.
He is a former Commissioner at
FDA from 2002 to 2004, and as the
former Administrator at the Centers
for Medicare & Medicaid Services
for the US Department of Health
and Human Services from 2004 to
2006. From 2001 to 2002, he
served as a member of the
President's Council of Economic
Advisers and Senior Director for
health care policy at the White
House. During President William J.
Clinton's administration, he held
the position as Deputy Assistant
Secretary of the Treasury for
economic policy. Previously, he
served as an Associate Professor of
economics and medicine at
Stanford University, where he also
directed the Program on Health
Outcomes Research. Currently, he
served as a Director at Reagan-
Udall Foundation for the Food and
Drug Administration. He was a
Director at Aviv REIT from 2013
until 2015.
Anne M. Director Non 2012 69 Ms. Anne M. Mulcahy has been a
Mulcahy Executive Director at J&J since 2012. She
Board served as the Chairman and Chief
Executive Officer at Xerox
Corporation (Xerox) until 2009.
Previously, Ms. Mulcahy also held
various positions at Xerox,
including President and Chief
Operating Officer; President of
Xerox's General Markets
Operations; Vice President for
Human Resources; and Vice
President and Staff Officer for
Customer Operations. Currently,
she serves as a Director at Target
Corporation, Graham Holdings
Company, and LPL Financial
Holdings. Ms. Mulcahy has also
been the Chairperson at Save the

Johnson & Johnson
Children since 2010.

A. Eugene Director Non 2012 71 Mr. A. Eugene Washington has
Washington Executive been a Director at J&J since 2012.
Board Currently, he serves as the
President and Chief Executive
Officer at the Duke University
Health System, and the Chancellor
for Health Affairs at Duke
University. Previously, he was the
Vice Chancellor of Health
Sciences, Dean of the David Geffen
School of Medicine at UCLA;
Chief Executive Officer at the
UCLA Health System; and
Distinguished Professor of
Gynecology and Health Policy at
UCLA. He also held the position as
Executive Vice Chancellor and
Provost at the University of
California, San Francisco (UCSF)
from 2004 to 2010. He also Co-
founded UCSF's Medical
Effectiveness Research Center for
Diverse Populations in 1993 and
served as its Director until 2005.
He served on the Chair of the
Department of Obstetrics,
Gynecology, and Reproductive
Sciences at UCSF from 1996 to
2004. He also Co-founded the
UCSF-Stanford Evidence-based
Practice Center and served as its
first Director from 1997 to 2002.
Earlier, he was with the Centers for
Disease Control and Prevention. He
was elected to the National
Academy of Sciences Institute of
Medicine in 1997, where he served
on its governing Council. He also
served as the Chairman of the
Board of Directors at the California
HealthCare Foundation and The
California Wellness Foundation in
the past. Currently, he is a Director
at Kaiser Foundation Hospitals and
Kaiser Foundation Health Plan.
Ian E. L. Director Non 2010 71 Mr. Davis has been an Independent
Davis Executive Director at J&J since 2010. He is
Board currently a Senior Advisor at Apax

Johnson & Johnson
Partners, a private equity firm; and

the Non Executive Chairman at
Rolls-Royce Holdings. He retired
from McKinsey & Company
(management consulting) as a
Senior Partner in 2010. He also
served as the Chairman and
Worldwide Managing Director at
McKinsey & Company from 2003
to 2009. Mr. Davis spent over 30
years at McKinsey & Company and
served as a consultant to various
global organizations across the
public, private and not-for-profit
sectors. He also served as the
Managing Partner of McKinsey &
Company's practice in the UK and
Ireland in the past. Currently, Mr.
Davis is a Director at Teach for All,
Majid Al Futtaim Holding, and BP.
Elizabeth General Senior 2022
Forminard Counsel Management
Jessica Vice Senior 2021
Moore President - Management
Investor
Relations
Michael H. General Senior 2016 63 Mr. Michael H. Ullmann has been
Ullmann Counsel Management the Executive Vice President and
the General Counsel at J&J since
2016. Earlier, he served as the
General Counsel of the Worldwide
Medical Devices and Diagnostics
Group at the company for six years.
Mr. Ullmann was also the
Corporate Secretary at J&J from
1999 to 2006. He joined the
company as mergers and
acquisitions Attorney in 1989. Mr.
Ullmann also serves as a member
of the Board of Trustees at the
Princeton Area Community
Foundation and the Rutgers
Institute for Ethical Leadership
Executive Business Cabinet.
Kathryn E. Executive Senior 2018 56 Ms. Wengel serves as the
Wengel Vice Management Executive Vice President and Chief
President Global Supply Chain Officer at the
company. Previously, she served as

Johnson & Johnson
the Vice President of Quality and

Compliance and the first Chief
Quality Officer at the company.
She has also held various strategic
leadership and executive roles of
increasing responsibility at J&J in
the past. Ms. Wengel joined the
Company in 1988 as the Project
Engineer and Engineering
Supervisor at Janssen.
Peter M. Executive Senior 2016 59 Mr. Fasolo serves as the Chief
Fasolo Vice Management Human Resources Officer and
President Executive Vice President at J&J
since 2016. Previously, he served
as the Vice President of Global
Talent Management and Vice
President of Global Human
Resources at the company. Mr.
Fasolo joined the company in 2004
as the Vice President of Human
Resources at Cordis Corporation.
He served Kravis Roberts & Co. as
the Chief Talent Officer for the
portfolio companies. He has over
25 years of global experience in
healthcare. Mr. Fasolo also serves
on the Board of the Human
Resources Policy Association in
Washington, Arm in Arm of
Mercer County and the
international charity Save the
Children.
Kurt Van Chief Senior 2022 Mr. Kurt Van den Bosch has been
den Bosch Financial Management the Chief Financial Officer of the
Officer company since May 2022. Prior to
this he served as a vice president of
mid-sized markets for J&J
MedTech's Europe, the Middle East
and Africa regions.
Johnson & Johnson- Company Statement
A statement from the Management's Discussion and Analysis is given below. It has
been taken from the company's 2021 10-K filing.
Johnson & Johnson and its subsidiaries (the Company) have approximately 141,700
employees worldwide engaged in the research and development, manufacture and sale
of a broad range of products in the healthcare field. The Company conducts business

Johnson & Johnson
in virtually all countries of the world with the primary focus on products related to
human health and well-being.
The Company is organized into three business segments: Consumer Health,

Pharmaceutical and Medical Devices. The Consumer Health segment includes a broad
range of products used in the Baby Care, Oral Care, Skin Health/Beauty, Over-the-
Counter pharmaceutical, Women’s Health and Wound Care markets. These products
are marketed to the general public and sold online (eCommerce) and to retail outlets
and distributors throughout the world. The Pharmaceutical segment is focused on six
therapeutic areas, including Immunology, Infectious diseases, Neuroscience,
Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic diseases.
Products in this segment are distributed directly to retailers, wholesalers, distributors,
hospitals and healthcare professionals for prescription use. The Medical Devices
segment includes a broad range of products used in the Orthopaedic, Surgery,
Interventional Solutions (cardiovascular and neurovascular) and Vision fields. These
products are distributed to wholesalers, hospitals and retailers, and used principally in
the professional fields by physicians, nurses, hospitals, eye care professionals and
clinics.
The Executive Committee of Johnson & Johnson is the principal management group
responsible for the strategic operations and allocation of the resources of the
Company. This Committee oversees and coordinates the activities of the Consumer
Health, Pharmaceutical and Medical Devices business segments.
In all of its product lines, the Company competes with other companies both locally
and globally, throughout the world. Competition exists in all product lines without
regard to the number and size of the competing companies involved. Competition in
research, involving the development and the improvement of new and existing
products and processes, is particularly significant. The development of new and
innovative products, as well as protecting the underlying intellectual property of the
Company's product portfolio, is important to the Company’s success in all areas of its
business. The competitive environment requires substantial investments in continuing
research. In addition, the development and maintenance of customer demand for the
Company’s consumer products involves significant expenditures for advertising and
promotion.
With “Our Credo” as the foundation, the Company’s purpose is to blend heart,
science and ingenuity to profoundly change the trajectory of health for humanity. The
Company is committed to bringing its full breadth and depth to ensure health for
people today and for future generations. United around this common ambition, the
Company is poised to fulfill its purpose and successfully meet the demands of the
rapidly evolving markets in which it competes.
The Company is broadly based in human healthcare, and is committed to creating

value by developing accessible, high quality, innovative products and services. New
products introduced within the past five years accounted for approximately 25% of
2021 sales. In 2021, $14.7 billion was invested in research and development reflecting
management’s commitment to create life-enhancing innovations and to create value
through partnerships that will profoundly change the trajectory of health for humanity.

Johnson & Johnson
A critical driver of the Company’s success is the diversity of its 141,700 employees
worldwide. Employees are empowered and inspired to lead with the Company’s Our
Credo and purpose as guides. This allows every employee to use the Company’s reach
and size to advance the Company's purpose, and to also lead with agility and urgency.
Leveraging the extensive resources across the enterprise enables the Company to
innovate and execute with excellence. This ensures the Company can remain focused
on addressing the unmet needs of society every day and invest for an enduring impact,
ultimately delivering value to its patients, consumers and healthcare professionals,
employees, communities and shareholders.
The net impact of acquisitions and divestitures on the worldwide sales growth was a
negative impact of 0.6% in 2021 and a negative impact of 0.3% in 2020.
Sales by U.S. companies were $47.2 billion in 2021 and $43.1 billion in 2020. This
represents increases of 9.3% in 2021 and 2.5% in 2020. Sales by international
companies were $46.6 billion in 2021 and $39.5 billion in 2020. This represents an
increase of 18.2% in 2021 and a decrease of 1.3% in 2020.
The five-year compound annual growth rates for worldwide, U.S. and international
sales were 5.5%, 4.5% and 6.5%, respectively. The ten-year compound annual growth
rates for worldwide, U.S. and international sales were 3.7%, 5.0% and 2.6%,
respectively.
In 2021, sales by companies in Europe achieved growth of 24.3% as compared to the
prior year, which included operational growth of 20.7% and a positive currency
impact of 3.6%. Sales by companies in the Western Hemisphere (excluding the U.S.)
achieved growth of 7.8% as compared to the prior year, which included operational
growth of 7.3% and a positive currency impact of 0.5%. Sales by companies in the
Asia-Pacific, Africa region achieved growth of 14.1% as compared to the prior year,
including operational growth of 11.4% and a positive currency impact of 2.7%.
The Company estimated that the inclusion of a 53rd week in the fiscal year 2020
results negatively impacted the 2021 comparative sales growth by approximately
1.0%. (See Note 1 to the Consolidated Financial Statements for Annual Closing Date
details). While the additional week added a few days to sales, it also added a full
week's worth of operating costs; therefore, the net earnings impact was negligible.
In 2021, the Company utilized three wholesalers distributing products for all three
segments that represented approximately 14.0%, 11.0% and 11.0% of the total
consolidated revenues. In 2020, the Company had three wholesalers distributing
products for all three segments that represented approximately 16.0%, 12.0% and
12.0% of the total consolidated revenues.
In fiscal year 2021, the Company recorded a partial IPR&D charge of $0.9 billion
primarily related to expected development delays in the general surgery digital
robotics platform (Ottava) acquired with the Auris Health acquisition in 2019. The
impairment charge was calculated based on revisions to the discounted cash flow
valuation model reflecting a delay of first in human procedures of approximately two
years from the initial acquisition model assumption of the second half of 2022. The
Company will continue to monitor the remaining $1.5 billion Ottava platform
intangible asset as development program activities are ongoing. In fiscal year 2020,

Johnson & Johnson
the Company recorded an IPR&D charge of $0.2 billion primarily related to a partial
impairment due to timing and progression of one of the digital surgery platforms
acquired with the Auris Health acquisition.
On January 28, 2022, subsequent to the fiscal year 2021, additional information
regarding efficacy became available which led the Company to the decision to
terminate the development of bermekimab for Atopic Dermatitis (AD). The Company
recorded an intangible asset impairment charge of approximately $0.6 billion related
to an in-process research and development asset, bermekimab (JnJ-77474462), an
investigational drug for the treatment of AD and Hidradenitis Suppurativa (HS). The
impairment charge is related to the AD indication and is a nonrecognized subsequent
event and will be reflected in the first quarter 2022 financial statements. The
Company acquired all rights to bermekimab from XBiotech, Inc. in fiscal year 2020.
Johnson & Johnson- Locations & Subsidiaries
Head office
One Johnson & Johnson Plaza

New Brunswick
United States of America
08933
1 732 5242455
Other Locations & Subsidiaries
Johnson & Johnson, Other locations
One Johnson & Johnson Plaza

New Brunswick
08933
1 732 5242455
Johnson & Johnson, Subsidiaries
Janssen Biotech, Inc.
800 Ridgeview Drive

Horsham
Pennsylvania 19044
Germany
1 215 325 3562
Cilag AG
Hochstrasse 201
Schaffhausen

Johnson & Johnson
Switzerland
41 52 6309111
Acclarent Inc
33 Technology Drive
Irvine
1 650 6875888
Biosense Webster Inc
3333 Diamond Canyon Road

Diamond Bar
Ethicon US LLC
4545 Creek Road

Cincinnati
1 513 3377000
Johnson & Johnson Vision Care Inc
7500 Centurion Parkway

Jacksonville
Mentor Worldwide LLC
Suite 200
33 Technology Drive
Irvine
1 805 8796000
Synthes Inc
1302 Wrights Lane East

West Chester
1 610 7195000
Vogue International
2600 McCormick Drive

Clearwater

Johnson & Johnson
Summarized Statement
Johnson & Johnson, Annual Statements
Parameter Name Currency 2018 2019 2020 2021 2022
Income Statements
Total Revenue USD 81581.00 82059.00 82584.00 93775.00 94943.00
Gross Profit USD 54595.00 54603.00 54257.00 63920.00 63954.00
Operating Income USD 17999.00 17328.00 16497.00 22776.00 21725.00
Net Income USD 15297.00 15119.00 14714.00 20878.00 17941.00
Diluted
USD 06.92 07.87 06.99 09.22 08.68
Normalized EPS
Balance Sheet
Total Current
USD 46033.00 45274.00 51237.00 60979.00 55294.00
Assets
Total Assets USD 152954.00 157728.00 174894.00 182018.00 187378.00
Total Current
USD 31230.00 35964.00 42493.00 45226.00 55802.00
Liabilities
Total Liabilities USD 93202.00 98257.00 111616.00 107995.00 110574.00
Total Equity USD 59752.00 59471.00 63278.00 74023.00 76804.00
Total Common
Shares USD 2662.32 2632.51 2632.51 2628.97 2613.60
Outstanding
Cash Flow
Cash from
Operating USD 22201.00 23416.00 23536.00 23410.00 21194.00
Activities
Cash from
Investing USD -3167.00 -6194.00 -20825.00 -8683.00 -12371.00
Activities
Cash from
Financing USD -18510.00 -18015.00 -6120.00 -14047.00 -8871.00
Activities
Net Change in
USD 283.00 -802.00 -3320.00 502.00 -360.00
Cash
Detailed Statement
Johnson & Johnson, Full Annual Statements
Parameter Name Currency 2018 2019 2020 2021 2022

Johnson & Johnson
Income Statements
Revenue USD 81581.00 82059.00 82584.00 93775.00 94943.00
Cost of Revenue,
USD 26986.00 27456.00 28327.00 29855.00 30989.00
Total
Selling/ General/
Admin. Expenses, USD 22540.00 22178.00 22084.00 24659.00 24765.00
Total
Research &
USD 10775.00 11355.00 12159.00 14714.00 14603.00
Development
Unusual Expense
USD 1826.00 1456.00 4428.00 4041.00 5004.00
(Income)
Other Operating
USD 1061.00 2469.00 -501.00 -1900.00 -2957.00
Expenses, Total
Total Operating
USD 63582.00 64731.00 66087.00 70999.00 73218.00
Expense
Net Income
USD 17999.00 17328.00 16497.00 22776.00 21725.00
Before Taxes
Provision for
USD 2702.00 2209.00 2083.00 1898.00 3784.00
Income Taxes
Net Income After
USD 15297.00 15119.00 14414.00 20878.00 17941.00
Taxes
Net Income
Before Extra. USD 15297.00 15119.00 14414.00 20878.00 17941.00
Items
Total
Extraordinary USD 00.00 00.00 300.00 00.00 00.00
Items
Income Available
to Com Excl USD 15297.00 15119.00 14414.00 20878.00 17941.00
ExtraOrd
Income Available
to Com Incl USD 15297.00 15119.00 14714.00 20878.00 17941.00
ExtraOrd
Diluted Net
USD 15297.00 15119.00 14714.00 20878.00 17941.00
Income
Diluted Weighted
USD 2728.70 2684.30 2670.70 2674.00 2663.90
Average Shares
Diluted EPS
Excluding USD 05.61 05.63 05.40 07.81 06.73
ExtraOrd Items
DPS - Common
Stock Primary USD 03.54 03.75 03.98 04.19 04.45
Issue

Johnson & Johnson
Balance Sheet
Cash USD 2619.00 2637.00 2863.00 2936.00 4926.00
Cash &
USD 3397.00 2864.00 2102.00 1901.00 5368.00
Equivalents
Short Term
USD 13671.00 13786.00 20220.00 26771.00 13225.00
Investments
Cash and Short
USD 19687.00 19287.00 25185.00 31608.00 23519.00
Term Investments
Accounts
Receivable - USD 14098.00 14481.00 13576.00 15283.00 16160.00
Trade, Net
Total Receivables,
USD 14098.00 14481.00 13576.00 15283.00 16160.00
Net
Total Inventory USD 8599.00 9020.00 9344.00 10387.00 12483.00
Prepaid Expenses USD 2699.00 2392.00 3132.00 3701.00 3132.00
Other Current
USD 950.00 94.00 00.00 00.00 00.00
Assets, Total
Property/ Plant/
Equipment, Total USD 41851.00 44289.00 47804.00 48579.00 50353.00
- Gross
Accumulated
Depreciation, USD -24816.00 -25674.00 -28038.00 -28717.00 -29450.00
Total
Property/ Plant/
Equipment, Total USD 17035.00 18615.00 19766.00 19862.00 20903.00
- Net
Goodwill, Net USD 30453.00 33639.00 36393.00 35246.00 45231.00
Intangibles, Net USD 47611.00 47643.00 53402.00 46392.00 48325.00
Long Term
USD 511.00 1148.00 1481.00 1884.00 576.00
Investments
Other Long Term
USD 11311.00 11409.00 12615.00 17655.00 17049.00
Assets, Total
Accounts Payable USD 7537.00 8544.00 9505.00 11055.00 11703.00
Accrued Expenses USD 20079.00 23952.00 28965.00 29293.00 29201.00
Notes Payable/
USD 00.00 00.00 832.00 1635.00 11220.00
Short Term Debt
Current Port. of
LT Debt/ Capital USD 2297.00 1202.00 1799.00 2131.00 1551.00
Leases
Other Current
USD 1317.00 2266.00 1392.00 1112.00 2127.00
liabilities, Total
Long Term Debt USD 27684.00 26494.00 32635.00 29985.00 26888.00
Total Long Term
USD 27684.00 26494.00 32635.00 29985.00 26888.00
Debt

Johnson & Johnson
Total Debt USD 29981.00 27696.00 35266.00 33751.00 39659.00

Deferred Income
USD 7506.00 5958.00 7214.00 7487.00 6374.00
Tax
Other Liabilities,
USD 26782.00 29841.00 29274.00 25297.00 21510.00
Total
Preferred Stock -
Non Redeemable, USD 00.00 00.00 00.00 00.00 00.00
Net
Common Stock,
USD 3120.00 3120.00 3120.00 3120.00 3120.00
Total
Retained Earnings
(Accumulated USD 106216.00 110659.00 113890.00 123060.00 128345.00
Deficit)
Treasury Stock -
USD -34362.00 -38417.00 -38490.00 -39099.00 -41694.00
Common
Unrealized Gain
USD 00.00 00.00 01.00 -03.00 -27.00
(Loss)
Other Equity,
USD -15222.00 -15891.00 -15243.00 -13055.00 -12940.00
Total
Total Liabilities &
Shareholders' USD 152954.00 157728.00 174894.00 182018.00 187378.00
Equity
Cash Flow
Net Income/
USD 15297.00 15119.00 14714.00 20878.00 17941.00
Starting Line
Depreciation/
USD 6929.00 7009.00 7231.00 7390.00 6970.00
Depletion
Deferred Taxes USD -1016.00 -2476.00 -1141.00 -2079.00 -1663.00
Non-Cash Items USD 988.00 -101.00 42.00 1459.00 1957.00
Changes in
USD 03.00 3865.00 2690.00 -4238.00 -4011.00
Working Capital
Capital
USD -3670.00 -3498.00 -3347.00 -3652.00 -4009.00
Expenditures
Other Investing
Cash Flow Items, USD 503.00 -2696.00 -17478.00 -5031.00 -8362.00
Total
Financing Cash
USD -148.00 575.00 -627.00 395.00 65.00
Flow Items
Total Cash
USD -9494.00 -9917.00 -10481.00 -11032.00 -11682.00
Dividends Paid
Issuance
(Retirement) of USD -4919.00 -5792.00 -2107.00 -2420.00 -4706.00
Stock, Net
Issuance
USD -3949.00 -2881.00 7095.00 -990.00 7452.00
(Retirement) of

Johnson & Johnson
Debt, Net
Foreign Exchange
USD -241.00 -09.00 89.00 -178.00 -312.00
Effects
Cash Interest Paid USD 1049.00 995.00 904.00 990.00 1915.00
Cash Taxes Paid USD 4570.00 4191.00 4619.00 4768.00 5223.00
Summarized Interim Statement
Johnson & Johnson, Summarized Interim Statements
Apr-2022 (3 Jul-2022 (3 Oct-2022 (3 Jan-2023 (3

Income Statements Currency
Months) Months) Months) Months)
Total Revenue USD 23426.00 24020.00 23791.00 23706.00
Gross Profit USD 15844.00 16118.00 15997.00 15995.00
Operating Income USD 5862.00 5840.00 5822.00 4201.00
Net Income USD 5149.00 4814.00 4458.00 3520.00
Diluted Normalized
USD 02.41 02.12 01.94 02.02
EPS
Balance Sheet
Total Current Assets USD 60424.00 63847.00 65236.00 55294.00
Total Assets USD 178355.00 177724.00 175124.00 187378.00
Total Current
USD 43390.00 44821.00 45543.00 55802.00
Liabilities
Total Liabilities USD 103646.00 101367.00 100525.00 110574.00
Total Equity USD 74709.00 76357.00 74599.00 76804.00
Total Common
USD 2629.38 2629.03 2616.88 2613.60
Shares Outstanding
Cash Flow
Cash from Operating
USD 3979.00 9560.00 15844.00 21194.00
Activities
Cash from Investing
USD -3634.00 -6273.00 -7974.00 -12371.00
Activities
Cash from Financing
USD -4385.00 -6646.00 -10571.00 -8871.00
Activities
Net Change in Cash USD -4024.00 -3504.00 -3132.00 -360.00
Detailed Interim Statement
Johnson & Johnson, Detailed Interim Statement
Apr-2022 Jul-2022 (3 Oct-2022 Jan-2023

Income Statements Currency
(3 Months) Months) (3 Months) (3 Months)
Revenue USD 23426.00 24020.00 23791.00 23706.00

Johnson & Johnson
Cost of Revenue, Total USD 7582.00 7902.00 7794.00 7711.00

Selling/ General/
USD 5938.00 6226.00 6089.00 6512.00
Admin. Expenses, Total
Research &
USD 3462.00 3703.00 3597.00 3841.00
Development
Unusual Expense
USD 1382.00 828.00 723.00 1871.20
(Income)
Other Operating
USD -1188.00 -553.00 -335.00 -353.20
Expenses, Total
Total Operating Expense USD 17564.00 18180.00 17969.00 19505.00
Net Income Before
USD 5862.00 5840.00 5822.00 4201.00
Taxes
Provision for Income
USD 713.00 1026.00 1364.00 681.00
Taxes
Net Income After Taxes USD 5149.00 4814.00 4458.00 3520.00
Net Income Before
USD 5149.00 4814.00 4458.00 3520.00
Extra. Items
Income Available to
USD 5149.00 4814.00 4458.00 3520.00
Com Excl ExtraOrd
Income Available to
USD 5149.00 4814.00 4458.00 3520.00
Com Incl ExtraOrd
Diluted Net Income USD 5149.00 4814.00 4458.00 3520.00
Diluted Weighted
USD 2666.50 2667.90 2661.30 2653.10
Average Shares
Diluted EPS Excluding
USD 01.93 01.80 01.68 01.33
ExtraOrd Items
DPS - Common Stock
USD 01.06 01.13 01.13 01.13
Primary Issue
Balance Sheet
Cash USD 3128.00 3337.00 4037.00 4926.00
Cash & Equivalents USD 1579.00 1968.00 1516.00 5368.00
Short Term Investments USD 25681.00 27263.00 28526.00 13225.00
Cash and Short Term
USD 30388.00 32568.00 34079.00 23519.00
Investments
Accounts Receivable -
USD 15594.00 16139.00 15890.00 16160.00
Trade, Net
Total Receivables, Net USD 15594.00 16139.00 15890.00 16160.00
Total Inventory USD 10990.00 11437.00 11675.00 12483.00
Prepaid Expenses USD 3452.00 3703.00 3592.00 3132.00
Property/ Plant/
Equipment, Total - USD 47702.00 47144.00 46681.00 49253.00
Gross
Accumulated
USD -29001.00 -28790.00 -28529.00 -29450.00
Depreciation, Total

Johnson & Johnson
Property/ Plant/
USD 18701.00 18354.00 18152.00 20903.00
Equipment, Total - Net
Goodwill, Net USD 34935.00 34166.00 33383.00 45231.00
Intangibles, Net USD 44420.00 42408.00 40336.00 48325.00
Long Term Investments USD 1452.00 1340.00 1884.00 576.00
Other Long Term
USD 18423.00 17609.00 16133.00 17049.00
Assets, Total
Accounts Payable USD 9309.00 9765.00 10153.00 11703.00
Accrued Expenses USD 28076.00 28771.00 28980.00 29201.00
Notes Payable/ Short
USD 3800.00 3800.00 3900.00 11220.00
Term Debt
Current Port. of LT
USD 497.00 505.00 524.00 1551.00
Debt/ Capital Leases
Other Current liabilities,
USD 1708.00 1980.00 1986.00 2127.00
Total
Long Term Debt USD 28851.00 28292.00 27603.00 26888.00
Total Long Term Debt USD 28851.00 28292.00 27603.00 26888.00
Total Debt USD 33148.00 32597.00 32027.00 39659.00
Deferred Income Tax USD 6424.00 5015.00 4946.00 6374.00
Other Liabilities, Total USD 24981.00 23239.00 22433.00 21510.00
Preferred Stock - Non
USD 00.00 00.00 00.00 00.00
Redeemable, Net
Common Stock, Total USD 3120.00 3120.00 3120.00 3120.00
Retained Earnings
USD 124380.00 126216.00 127917.00 128345.00
(Accumulated Deficit)
Treasury Stock -
USD -39034.00 -39136.00 -41146.00 -41694.00
Common
Unrealized Gain (Loss) USD -16.00 -36.00 -38.00 -27.00
Other Equity, Total USD -13741.00 -13807.00 -15254.00 -12940.00
Total Liabilities &
USD 178355.00 177724.00 175124.00 187378.00
Shareholders' Equity
Cash Flow
Net Income/ Starting
USD 5149.00 9963.00 9963.00 17941.00
Line
Depreciation/ Depletion USD 1769.00 3513.00 3513.00 6970.00
Deferred Taxes USD -926.00 -2349.00 -2349.00 -1663.00
Non-Cash Items USD 726.00 1175.00 1175.00 1957.00
Changes in Working
USD -2739.00 -2742.00 -2742.00 -4011.00
Capital
Capital Expenditures USD -607.00 -1470.00 -1470.00 -4009.00
Other Investing Cash
USD -3027.00 -4803.00 -4803.00 -8362.00
Flow Items, Total
Financing Cash Flow USD -373.00 802.00 802.00 65.00

Johnson & Johnson
Items
Total Cash Dividends
USD -2787.00 -5758.00 -5758.00 -11682.00
Paid
Issuance (Retirement) of
USD -1256.00 -1730.00 -1730.00 -4706.00
Stock, Net
Issuance (Retirement) of
USD 31.00 40.00 40.00 7452.00
Debt, Net
Foreign Exchange
USD 16.00 -145.00 -145.00 -312.00
Effects
Capital Market Ratios
Johnson & Johnson, Capital Market Ratios
March 09,
Key Ratios
2023
P/E (Price/Earnings) Ratio 22.36
EV/EBITDA (Enterprise Value/Earnings Before Interest, Taxes,
14.54
Depreciation and Amortization)
Enterprise Value/Sales 04.39
Enterprise Value/Operating Profit 19.21
Enterprise Value/Total Assets 02.23
Dividend Yield 02.91
Market Cap 394835.80
Enterprise Value 417252.20
Interim Ratios
Johnson & Johnson, Interim Ratios
April - July - October January

Key Ratios Unit/Currency Ratio Type
2022 2022 - 2022 - 2023
EPS (Earnings per Equity
USD 01.93 01.80 01.68 01.33
Share) Ratios
Equity
Dividend per Share USD 01.06 01.13 01.13 01.13
Ratios
Equity
Book Value per Share USD 28.41 29.04 28.51 29.39
Ratios
Profitability
Gross Margin % 67.63 67.10 67.24 67.47
Ratios
Profitability
Operating Margin % 25.02 24.31 24.47 17.72
Ratios
Profitability
Net Profit Margin % 21.98 20.04 18.74 14.85
Ratios

Johnson & Johnson
Profitability
Profit Markup % 208.97 203.97 205.25 207.43
Ratios
PBIT Margin (Profit Profitability
% 00.00 00.00 00.00 32.07
Before Interest & Tax) Ratios
PBT Margin (Profit Profitability
% 25.02 24.31 24.47 17.72
Before Tax) Ratios
Operating Costs (% of
% 74.98 75.69 75.53 82.28 Cost Ratios
Sales)
Administration Costs
% 25.35 25.92 25.59 27.47 Cost Ratios
(% of Sales)
Interest Costs (% of
% 00.00 00.00 00.00 00.81 Cost Ratios
Sales)
Liquidity
Current Ratio Absolute 01.39 01.42 01.43 00.99
Ratios
Liquidity
Quick Ratio Absolute 01.14 01.17 01.18 00.77
Ratios
Leverage
Debt to Equity Ratio Absolute 00.44 00.43 00.43 00.52
Ratios
Leverage
Net Debt to Equity Absolute 00.46 00.45 00.46 00.51
Ratios
Leverage
Debt to Capital Ratio Absolute 00.25 00.25 00.25 00.30
Ratios
Interest Coverage Leverage
Absolute 00.00 00.00 00.00 3980.77
Ratio Ratios
Annual Ratios
Johnson & Johnson, Annual Ratios
Ratio Type Key Ratios Unit/Currency 2022 2021 2020 2019 2018
Growth
Sales Growth % 01.25 13.55 00.64 00.59 06.71
Ratios
Operating
Growth
Income % -04.61 38.06 -04.80 -03.73 01.84
Ratios
Growth
Growth EBITDA
% -04.88 27.13 -02.50 -02.37 06.92
Ratios Growth
Growth Net Income
% -14.07 41.89 -02.68 -01.16 1076.69
Ratios Growth
Growth
EPS Growth % -05.89 32.01 -11.24 13.70 11.11
Ratios
Growth Working
% -103.22 80.16 -06.08 -37.11 17.94
Ratios Capital Growth
Equity EPS (Earnings
USD 08.68 09.22 06.99 07.87 06.92
Ratios per Share)

Johnson & Johnson
Equity Dividend per

USD 04.45 04.19 03.98 03.75 03.54
Ratios Share
Equity Dividend
Absolute 01.95 02.20 01.76 02.10 01.96
Ratios Cover
Equity Book Value
USD 29.39 28.16 24.04 22.59 22.44
Ratios per Share
Equity Cash Value per
USD 03.94 01.84 01.89 02.09 02.26
Ratios Share
Profitability
Gross Margin % 67.36 68.16 65.70 66.54 66.92
Ratios
Profitability Operating
% 22.88 24.29 19.98 21.12 22.06
Ratios Margin
Profitability Net Profit
% 18.90 22.26 17.82 18.42 18.75
Ratios Margin
Profitability
Profit Markup % 206.38 214.10 191.54 198.87 202.31
Ratios
PBT Margin
Profitability
(Profit Before % 22.88 24.29 19.98 21.12 22.06
Ratios
Tax)
Profitability Return on
% 23.36 28.20 23.25 25.42 25.60
Ratios Equity
Return on
Profitability
Capital % 16.51 16.65 12.46 14.23 14.79
Ratios
Employed
% 09.71 11.70 08.85 09.73 09.86
Ratios Assets
% 106.59 114.95 85.96 97.21 105.75
Ratios Fixed Assets
Return on
Profitability
Working % -4276.57 144.58 188.67 186.12 121.59
Ratios
Capital
Operating
Cost Ratios Costs (% of % 77.12 75.71 80.02 78.88 77.94
Sales)
Administration
Cost Ratios Costs (% of % 26.08 26.30 26.74 27.03 27.63
Sales)
Liquidity
Current Ratio Absolute 00.99 01.35 01.21 01.26 01.47
Ratios
Liquidity
Quick Ratio Absolute 00.77 01.12 00.99 01.01 01.20
Ratios
Liquidity
Cash Ratio Absolute 00.18 00.11 00.12 00.15 00.19
Ratios
Leverage Debt to Equity
Absolute 00.52 00.46 00.56 00.47 00.50
Ratios Ratio
Leverage Net Debt to Absolute 00.21 00.03 00.16 00.14 00.17

Johnson & Johnson
Ratios Equity
Leverage Debt to Capital
Absolute 00.34 00.31 00.36 00.32 00.33
Ratios Ratio
Efficiency
Asset Turnover Absolute 00.51 00.53 00.50 00.53 00.53
Ratios
Efficiency Fixed Asset
Absolute 04.66 04.73 04.30 04.60 04.79
Ratios Turnover
Efficiency Inventory
Absolute 02.71 03.03 03.09 03.12 03.11
Ratios Turnover
Efficiency Current Asset
Absolute 01.63 01.67 01.71 01.80 01.83
Ratios Turnover
Capital
Efficiency
Employed Absolute 00.72 00.69 00.62 00.67 00.67
Ratios
Turnover
Working
Efficiency
Capital Absolute -186.90 05.95 09.44 08.81 05.51
Ratios
Turnover
Efficiency Revenue per
USD 670028.23 00.00 00.00 00.00 00.00
Ratios Employee
Efficiency Net Income per
USD 126612.56 00.00 00.00 00.00 00.00
Ratios Employee
Efficiency
Capex to Sales % 04.22 03.89 04.05 04.26 04.50
Ratios
Efficiency
R&D to Sales % 15.38 15.69 14.72 13.84 13.21
Ratios
Disclaimer:
All Rights Reserved.
This information has been extracted from MarketLine by a registered user
No part of this publication may be reproduced, stored in a retrieval system or

transmitted in any form by any means, electronic, mechanical, photocopying,
recording or otherwise, without the prior permission of the publisher, MarketLine.
The facts of this report are believed to be correct at the time of publication but cannot
be guaranteed. Please note that the findings, conclusions and recommendations that
MarketLine delivers will be based on information gathered in good faith from both
primary and secondary sources, whose accuracy we are not always in a position to
guarantee. As such MarketLine can accept no liability whatever for actions taken
based on any information that may subsequently prove to be incorrect.


MarketLineIC - Johnson Johnson - Profile - 120323

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

MarketLineIC - Johnson Johnson - Profile - 120323

Uploaded by

Copyright:

Available Formats

Johnson & Johnson

Published: 26 Feb 2023 Page 1

Published: 26 Feb 2023 Page 2

Johnson & Johnson- Financial and Strategic Analysis

Johnson & Johnson- Key Facts

Johnson & Johnson- Key Facts

Johnson & Johnson- Business Description

Johnson & Johnson (J&J or 'the company') is a manufacturer and marketer of

The company operates through three reportable business segments: Pharmaceutical,

The company’s Pharmaceutical segment produces and markets products in six

Published: 26 Feb 2023 Page 3

hypertension) and cardiovascular and metabolism (thrombosis and diabetes). The

J&J's Medical Devices segment manufactures and markets products used by

The company's Consumer Health segment develops, manufactures and markets

Johnson & Johnson- Major Products and Services

Johnson & Johnson- Major Products and Services

Pharmaceutical products: Aveeno

Published: 26 Feb 2023 Page 4

and metabolic diseases Le petite Marseillais

Johnson & Johnson- History

Johnson & Johnson- History

Published: 26 Feb 2023 Page 5

Statewide Insurance Corp. in Arizona.

Published: 26 Feb 2023 Page 6

Listing (EUL) to the WHO to investigate

Published: 26 Feb 2023 Page 7

2021 Regulatory Approval In May, J&J secured Mexico's health

Published: 26 Feb 2023 Page 8

Published: 26 Feb 2023 Page 9

2020 Contracts/Agreements In February, the company, along with a group

Published: 26 Feb 2023 Page 10

treatment of chronic hepatitis B virus

Published: 26 Feb 2023 Page 11

of new Asia Pacific Headquarters.

Published: 26 Feb 2023 Page 12

2017 Contracts/Agreements In August, J&J entered into a partnership with

Published: 26 Feb 2023 Page 13

2017 Contracts/Agreements In September, the company's Janssen

Published: 26 Feb 2023 Page 14

Pharmaceutical secured approval from China

Published: 26 Feb 2023 Page 15

evolving healthcare marketplace. As part of

Published: 26 Feb 2023 Page 16

with imminent risk for suicide.

Published: 26 Feb 2023 Page 17

being developed for the treatment and

Published: 26 Feb 2023 Page 18

product as an adjunctive hemostat across a

Published: 26 Feb 2023 Page 19

therapies. The FDA approved Darzalex

Published: 26 Feb 2023 Page 20

Tube Balloon Dilation System is the first

Published: 26 Feb 2023 Page 21

palmitate) is the first and only four-times-a-

Published: 26 Feb 2023 Page 22

for registration, distribution and

Published: 26 Feb 2023 Page 23

novel antivirals, including NVR 3-778. Novira

Published: 26 Feb 2023 Page 24

combination with Imbruvica (ibrutinib), an

Published: 26 Feb 2023 Page 25

2014 Contracts/Agreements DePuy Synthes entered into a commercial

Published: 26 Feb 2023 Page 26